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 List of abbreviations 
 
ACE    angiotensin-converting enzyme 
AD(T)P   adenosine di(tri)phosphate 
AF    atrial fibrillation 
ALC    atrial myosin light chain 
AU    arbitrary units 
cAMP    cyclic adenosine monophosphate  
cTn    cardiac troponin  
cTnFL    cardiac troponin complex containing full-length cTnI 
cTnDEG    cardiac troponin complex containing cTnI1-192 
cTnC    cardiac troponin C 
cTnI    cardiac troponin I 
cTnI1-192   truncated cardiac troponin I containing aminoacid residues 1-
192 
cTnT    cardiac troponin T 
DTT    dithiothreitol 
EGTA   ethylene glycol-bis (amino-ethylether) N,N,N′,N′-tetra acetic 
acid 
EC50    median effective concentration  
fapp (f)    rate constant of crossbridge attachment  
Fmax    maximal isometric force 
Fpass    passive force 
gapp (g)    rate constant of crossbridge detachment 
HF    heart failure 
IR    inhibitory region of troponin I 
kDa    kilodalton 
KACT    the rate of force rise 
KTR    rate of force redevelopment 
KREL,F    rate constant of the rapid phase of force relaxation 
KREL,S    rate constant of the slow phase of force relaxation 
LV    left ventricle 
  
LVEDP/ LVESP   left ventricular end-diastolic/systolic pressure 
MHC    myosin heavy chain 
MLC    myosin light chain 
mRNA    messenger RNA 
MyBPC   myosin binding protein C 
n    number of observations 
NADH    nicotineamide adenine dinucleotide 
nH    steepness of the force-pCa or ATPase-pCa relation 
NMR    nuclear magnetic resonance 
NYHA    New York heart association  
Pi    inorganic phosphate  
pCa50    mid-point of the force-pCa or ATPase-pCa relation 
PKA    protein kinase A 
ROS/RNS   reactive oxygen/nitrogen species 
SEM    standard error of the mean 
SERCA2a   sarcoplasmic reticulum Ca2+ ATPase 2a 
SDS-PAGE   sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SR    sinus rhythm 
TM    tropomyosin 
tSLOW    duration of the slow phase of force relaxation 
UV    ultraviolet 
V1    homodimer of α–myosin heavy chain 
VLC    ventricular myosin light chain 
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The incidence of heart failure is increasing worldwide. At present heart failure is a major 
cardiovascular problem afflicting about 22 million individuals in the world. It is the reason 
for 20% of all hospital admissions among people above 65 years of age. According to the 
Netherlands Heart Foundation there are currently around 200 000 people diagnosed with 
heart failure in the Netherlands. About 10% of patients with heart failure die within 1 year, 
and about 50% die within 5 years after diagnosis.1 Therefore, development of new 
therapeutical strategies for both prevention and treatment of this disease is of great 
importance. 
Heart failure (HF) (or Congestive Heart Failure) is the complex of signs and 
symptoms that occurs when the heart fails to pump an adequate cardiac output to meet the 
metabolic demands of the body. To compensate for the decreased cardiac output, the end-
diastolic volume of the failing heart increases. When the end-diastolic wall is stretched 
beyond the optimal length of its muscle fibres it composes, the ability of the heart to pomp 
the blood is reduced. This increases the venous and cardiac volume. Due to this progressive 
congestion of the veins and the heart with blood the expression a congestive heart failure is 
sometimes used. However, because not all patients have volume overload at the time of 
initial or subsequent evaluation, the term "heart failure" is preferred over the older term 
"congestive heart failure". 
The syndrome of heart failure may occur as the end-point of a number of 
cardiovascular diseases, such as ischemic heart disease, hypertension, idiopathic 
cardiomyopathy, valvular defects and atrial fibrillation.2,3 During the development of heart 
failure cardiac pump function declines.4 Several potential mechanisms have been described 
to underlie this process (Figure 1.1). 
 
General introduction 
13 
   
Figure 1.1. Potential mechanisms involved in heart failure. Abbreviations: LVESP and LVEDP denote 
left ventricular end-systolic and end-diastolic pressure, respectively. Adapted from5. 
 
End-stage heart failure often involves the general loss of functional myocytes, an 
increase of collagen content of the extracellular matrix (hyperplasia), ventricular chamber 
remodeling and decreased myocyte function. These processes lead to a gradual decrease in 
left ventricular end-systolic pressure (LVESP) and/or an increase in left ventricular end-
diastolic pressure (LVEDP). Eventually, the decline in cardiac pump function results in the 
clinical syndrome of heart failure.5 
It has been shown that in the end-stage failing human hearts, basal myocyte 
contractility is well preserved, while ‘contractility reserve’ (the ability to increase 
contractility with heart rate or sympathetic stimulation) is severely depressed.6-8 These 
changes in muscle performance and regulation can explain the poor pump function, reduced 
exercise capacity and tachycardia intolerance (i.e. inability to endure high heart beating 
rate) characteristic for the failing human heart.9 Depressed myocyte contractility is an 
important determinant of reduced pump function observed in heart failure.9 However, most 
data from clinical trials indicate that inotropic therapy aimed to enhance cellular 
contractility of the failing heart increases rather than decreases mortality.10 One explanation 
for the increased mortality is that this treatment, while increasing contractility, at the same 
time overstimulates signaling cascades (such as cAMP or calcium-calcineurin pathways) 
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that are already chronically activated. The current drug regimen consisting of β-blockers 
and ACE-inhibitors, which reduces neurohumoral stimulation of the heart proved to be 
beneficial,11,12 however the underlying cellular mechanisms of their action are largely 
unknown yet. New targeted heart failure therapies that would increase or maintain 
cardiomyocyte contractility by selectively modulating specific contractile proteins are of 
particular interest. Hence, knowledge about the specific primary mechanisms involved in 
the development of heart failure in human tissue is essential for the development of new 
clinical interventions for heart failure. 
At the molecular level, decreased cardiomyocyte function may be due to 
alterations in calcium handling, altered myofilament function, changes in the myocyte 
cytoskeleton, or a combination of these factors (Figure 1.1). The first evidence for a 
functional impairment at the myofilament level in failing human myocardium has been 
obtained more than 40 years ago.13 Alpert and Gordon13 demonstrated a markedly reduced 
myofibrillar ATPase activity in failing human hearts. Since then evidence for the 
involvement of myofilament protein alterations in heart failure has accumulated.5,14-18 
Changes in isoform composition, phosphorylation and degradation of both contractile and 
regulatory myofilament proteins and their functional consequences have been reported. 
However, the precise mechanism of myocyte dysfunction in heart failure remains largely 
unknown. In addition, the relative contribution of these alterations to in vivo cardiac pump 
function is not clear yet. 
 
Cardiac myofilament contraction 
Sarcomere structure 
A schematic representation of the contractile apparatus of striated muscle is shown in 
Figure 1.2. The major proteins of the thick and thin filaments are indicated. The top panel 
reflects the sarcomeric structure during diastole, while the bottom panel reflects systole. 
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Figure 1.2. Sarcomere structure. The major contractile and regulatory proteins are shown in diastole 
(top panel) and systole (bottom panel). The thin filament is composed of actin, tropomyosin, and the 
troponin complex (Tn-T, Tn-C, and Tn-I). The thick filament is composed of myosin containing a 
globular head portion (S1), a hinged stalk region (S2) and a rod section. The S1 portion is associated 
with two light chains 1 and 2 (MLC-1; MLC-2). The myosin rod section also contains the myosin 
binding protein C (MyBPC). Adopted from19. 
MyBPC 
MLC-2 
MLC-1 
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The thick filament is a bipolar polymer of the motor protein myosin that interacts 
with actin to produce force and sarcomere shortening. Myosin is composed of two heavy 
chains with a molecular mass of ~200 kDa each and four light chains with molecular 
masses of ~20-24 kDa each. The myosin heavy chains (MHC) form a parallel coiled-coil 
structure with a large, globular region at the end, termed head or S1 (subfragment 1).20 The 
myosin head is called a crossbridge, since this unit bridges the gap between the myosin 
and actin filaments in muscle. The site of the ATPase activity is located in the heads of the 
MHCs, which also carry the actin-binding site. Two different MHC isoforms are found in 
the human heart: the fast α- and the slow β-MHC. β-MHC predominates in the ventricles, 
while the atria contain a mixture of these two isoforms (β-MHC ranges from 0 to 29% of 
total MHC).21 One pair of myosin light chains binds to each myosin head. The myosin light 
chains form two subfamilies, the essential light chains (MLC-1) and the regulatory light 
chains (MLC-2). Two different essential MLC isoforms exist, characteristic for atrial and 
ventricular tissue (ALC-1 and VLC-1, respectively) and at least three regulatory MLC 
isoforms are present in human heart (atrial ALC-2 and ventricular VLC-2 and VLC-2*). 
The regulatory MLC-2 can be phosphorylated by Ca2+ -calmodulin activated myosin light 
chain kinase and by protein kinase C.22 The role of MLCs is to regulate force generating 
kinetics and thereby to tune cardiac function.23 Other proteins have been shown to also play 
an important role in the thick filament structure and function. Myosin binding protein C 
(MyBPC) has a 1–7 myosin stoichiometry. It forms a collar around part of the myosin 
molecules. It modulates myocyte contraction, but is also involved in the assembling of the 
contractile filaments. The large elastic molecule titin plays a major structural role in the 
sarcomere contributing to passive and possible active elasticity as well as sarcomere 
stability. The M-line proteins (myomesin and M-protein) provide struts connecting the 
thick filaments together in the centre of the sarcomere.24 
The main site for Ca2+ -regulation is the thin filament. The thin filament of cardiac 
muscle consists of actin, tropomyosin and the troponin complex (Figure 1.2).17 Actin is a 
globular protein that, under physiological conditions, polymerises into elongated filaments 
of double helical strands. Tropomyosin (TM) an elongated protein that spans seven actin 
monomers, lies in the groove between actin strands and is polymerised head-to-tail along 
the actin filament. Human cardiac TM is a dimer of two identical α–helical chains, which 
are wound around each other in a coiled coil. Associated with each TM is troponin (cTn), a 
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globular protein complex consisting of three subunits: troponin C (cTnC), the Ca2+ binding 
protein; troponin I (cTnI), which inhibits the actin-myosin interaction and troponin T 
(cTnT), which transduces the Ca2+ binding signal to TM. Recently a large part of the atomic 
structure of human cTn using x-ray crystallographic analysis has been resolved (Figure 
1.3).25 In this atomic model, cTnI consists of 2 helixes H1 and H2, interacting with cTnT, a 
flexible inhibitory region (IR, residues 137-148), helixes H3 and H4, and a C-terminal 
domain (residues 192- 210). The IR and C-terminal domain are both essential for the 
inhibitory binding of cTnI to actin-tropomyosin in the absence of Ca2+. 
In diastole, crossbridges are either blocked from interacting with actin by TM or in 
a weak, rapid binding-unbinding state with actin without generating force (Figure 1.2). In 
systole, activation of the thin filament by Ca2+ ions allows strong binding crossbridge 
states, associated with force generation and ATP hydrolysis. It has been proposed25 that the 
H3 helix of cTnI serves as a molecular switch, which at high Ca2+ concentration binds to 
cTnC (curled structure in Figure 1.3) and induces the detachment of IR and C-terminus 
from the actin filament, which through movement of TM allows the actin-myosin 
interactions. 
 
Figure 1.3. A schematic representation of the interactions between troponin and other thin 
filament components based on x-ray crystallographic analysis. The actin–tropomyosin-binding 
portions are schematically drawn: TnT1 and C-TnT are gray ellipsoids, and the inhibitory region (IR) 
and the C terminus of cTnI (C-TnI) are black ellipsoids. Light ellipsoids on the tropomyosin and actin 
represent sites of interaction with cTnT and cTnI. The solid arrows indicate the interactions between 
troponin and tropomyosin–actin.  
TnC 
Chapter 1 
18 
Three state models 
Biochemical26 and structural27 three-state models of thin filament regulation have been 
proposed. These biochemical and structural three-state models are comparable and provide 
complementary views of regulation, but are not necessarily equivalent. The data in this 
thesis are considered in the context of these models. 
In the biochemical three state model,26 tropomyosin can exist in equilibrium 
between blocked, closed and open states. These three states were termed analogous to terms 
describing an English shop: blocked (with a gate locked for overnight security), closed 
(with the door shut as at tea time or during lunch time), or open (for business). In the 
absence of Ca2+ ions, troponin stabilizes TM in a state that blocks any actin interaction with 
myosin (blocked state). In the presence of Ca2+, the equilibrium shifts and TM adopts a 
state that allows myosin to bind relatively weakly to actin (closed state). In the presence of 
myosin, equilibrium shifts yet again and TM adopts a state that permits myosin to bind 
strongly to actin, to hydrolyse ATP, and to cooperatively propagate further binding of 
myosin heads to actin (open state). 
In the structural three-state model27 the Ca2+-free troponin constrains TM in a 
position on actin that sterically blocks all, but weak myosin-binding sites. In the presence of 
Ca2+, troponin allows TM to move on the surface of the actin filament, which exposes some 
amino acids on actin that interact strongly with myosin. Subsequent binding of myosin 
further moves TM around the actin filament, which exposes all strong myosin-binding sites 
on actin. 
Brenner28 has suggested that Ca2+ controls the transition between the weakly and 
strongly attached crossbridge states (i.e. from blocked to closed state). This transition can 
be described by an attachment rate constant, fapp (or f), and a detachment rate constant, gapp 
(or g).28,29 The subscript apparent is used because both rate constants combine the rate 
constants of a number of steps in the actin-myosin ATPase cycle involving attachment of 
actin, various actin-myosin nucleotide states, and detachment. It has been found that gapp is 
independent of Ca2+ concentration, but fapp increases as a function of Ca2+. 
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Contractile protein alterations in HF 
Alterations in myofilament function in heart failure 
Alterations in myofilament function are attributed to changes in contractile proteins. In 
Figure 1.4 protein modification so far identified in HF are presented. 
 
 
 
 
 
 
 
 
Figure 1.4. Contractile protein alterations involved in heart failure. 
 
Translational modifications 
Translational modifications are changes that occur in protein expression at the level of 
translation (transition from mRNA to polypeptide chain). Such changes include mutations 
and protein isoform shifts. Mutations are changes in the base sequence of DNA that alter 
genetic information. Familial hypertrophic and dilated cardiomyopathies are characterized 
by mutations in contractile proteins.30 Over 300 dominant mutations in genes encoding 
sarcomere proteins were identified.31 The mutations in β-MHC (~35%), MyBPC (~15%) 
and cTnT (~15%) have been reported to be the most frequent.32 The severity and pattern of 
hypertrophy, age at onset of clinical manifestations, and progression to heart failure were 
found to be in part dependent on the precise sarcomere protein gene mutation. However, the 
pathophysiological mechanism how genetic mutations lead to functional defects are largely 
unknown. A putative cascade of events has been proposed33 for development of familial 
hypertrophic cardiomyopathy: the mutation leads to a poison polypeptide that would be 
incorporated into the sarcomere. This would alter the sarcomeric function that would result 
(1) in an altered cardiac function (impaired or improved depending on mutation) and then 
(2) in the alteration of the sarcomeric and myocyte structure (hypertrophy). Whether this 
mechanism is common for all familial cardiomyopathies and how exactly the alterations in 
Translational  Post-translational  
mutations isoform 
switch 
phosphorylation degradation 
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sarcomere alter the phenotype and the function of the human heart still remains to be 
established. 
Due to small differences in amino acid sequence, several forms of a protein may 
exist, which are called isoforms. In cardiac muscle different isoforms may be present of 
MHC, cTnT, MLC and titin. As indicated above in human myocardium the β-MHC 
isoform predominates in ventricles, whereas a variable mixture of α- and β-MHC is found 
in atria. During human heart failure the α-MHC fraction declines in both atria and 
ventricles.21,34 The functional implications of this MHC switch in human myocardium are 
still unclear. In addition, a MLC isoform switch was reported in human heart failure. The 
appearance of ALC-1 in ventricles (up to 10%) has been associated with increased velocity 
of shortening and Ca2+-sensitivity.35,36 It has been suggested that this switch is an important 
component of compensated ventricular remodeling that may play a role in delaying or 
preventing progression to heart failure.36 Also shifts from the adult cTnT to the less energy 
consuming fetal cTnT isoform37 and from the stiff N2B to the more compliant N2BA titin38 
isoform were reported. 
 
Post-translational modifications 
Modifications of proteins, which occur after the translation process are called post-
translational modifications. Such changes in contractile protein phosphorylation and 
degradation have been found in human heart failure.14,17 
Cardiac troponin I is less phosphorylated in human end-stage failing hearts 
compared to donor hearts and this correlated with an increased responsiveness of the 
cardiac myofilaments to Ca2+.39-41 Also changes in MLC-2 phosphorylation40 were observed 
in human tissue. The observed changes in contractile protein phosphorylation may be 
caused by a decreased activity of protein kinase A due to β-adrenergic desensitisation and 
receptor down-regulation and an increased activity of protein kinase C and protein 
phosphatases found in human heart failure.42,43 
Degradation of thin filament proteins has been observed as a result of ischemic 
injury to the heart. The release of degraded as well as intact cTnI and cTnT into the blood is 
a well-established test for the occurrence of myocardial infarction within the clinical 
setting.44 Cardiac TnI degradation was also found in viable cardiac tissue of patients with 
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Contractile protein studies in humans 
ischemic cardiomyopathies38,45,46 and has been associated with myocardial stunning, i.e. the 
reversible contractile dysfunction observed after abrupt periods of ischemia. The 
degradation of cytoskeleton proteins such as vinculin, desmin and α-actinin has been 
observed in infarcted human heart tissue as well.47 Thus, it is possible that damage to 
cytoskeleton proteins could contribute to the diminished contractility of failing 
myocardium.48 
 
Methodology 
To answer the question about the relative role of contractile protein alterations in the onset 
and progression of heart failure several methodological approaches can be used. 
Employment of transgenic animal models provides a popular possibility to study the effects 
of a protein modification on in vivo function of the heart and evaluate its impact on 
morbidity and mortality. Models mimicking contractile protein changes such as e.g. cTnI 
degradation45 and phosphorylation49 have been developed. However, the question remains 
whether these transgenic studies can be extrapolated to contractile protein alterations in 
humans. It has been shown that some pathological mechanisms (e.g. stunning) in rodents 
are different than in large animals.50 Besides, the results in transgenic mice models may be 
obscured by the species-specific development of compensatory mechanisms.51 
In humans two different strategies can be followed to investigate the functional 
consequences of contractile protein alterations (Figure 1.5). 
 
 
 
 
 
 
 
 
Figure 1.5. Methodology of contractile protein studies in human myocardium. 
 
Study of intrinsic properties 
The intrinsic variability in protein composition within human myocardium allows 
correlation of functional parameters with contractile protein composition. From these 
correlations the functional role of contractile protein alterations in heart failure can be 
derived. This methodology has been applied to study the role of MLC-2 and cTnI 
phosphorylation in human heart failure.40 In the experiments described in this thesis this 
Study of intrinsic properties  Exchange  
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approach was used to investigate the functional implications of the MHC isoform shift in 
heart failure. Using the variable expression of MHC isoforms in atrial and ventricular 
human tissue the functional characteristics of human α− and  β−MHC isoforms were 
determined. To study the role of MHC isoform shift in diseased human myocardium, 
mechanical and energetic properties were investigated in atrial trabeculae from healthy 
patients and patients with atrial fibrillation and in thin ventricular muscle strips from non-
failing donor and end-stage failing human hearts. 
 
Exchange 
This technique can be used to study the functional effects of an alteration in troponin 
subunit composition.52,53 In this thesis, exchange experiments were performed for the first 
time in human cardiac tissue to study the specific effects of C-terminal degradation of cTnI. 
To this end, the human cardiac full-length cTnI and truncated cTnI (cTnI1-192) peptides and 
other human troponin subunits (cTnT and cTnC) were expressed separately in Escherichia 
coli and purified using ion-exchange chromatography. The purified troponin subunits were 
reconstituted into the full troponin complex by mixing the subunits in a 1:1:1 molar ratio. 
The cardiac preparations were treated with an exchange solution containing an excess of 
troponin complex (ca 6 μM) with either full-length or truncated cTnI. In this way the 
troponin complex in the exchange solution kicks-off the endogenous complex and replaces 
it (Figure 1.6). 
The exchange process mimics the natural process of cTn subunit replacement in 
cardiac myofilaments, where troponin exchanges into preexisting sarcomeres at random 
locations every 6-7 days (in rat cardiac tissue).14 It has also been shown that exchange of 
the troponin complex is uniform and homogeneous along the myofilaments in cardiac 
myofibrils.54 The advantage of this technique is that it allows to investigate the direct effect 
of cTn subunit alterations on contractility of human cardiac preparations without additional 
effects of changes in other contractile proteins found in failing human tissue or 
compensatory protein changes, which may develop in transgenic animals. 
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Figure 1.6. Exchange of the full-length or truncated troponin complex in myofilaments. 
 
Aims of this study 
The main objective of this thesis was to elucidate the effect of translational and post-
translational alterations in contractile proteins occurring during heart failure on contractile 
function in human cardiac tissue. The shift of α- to β-MHC isoform was studied as an 
example of translational changes because this is a prominent feature in animal models of 
heart failure. The degradation of cTnI from its C-terminus was investigated as post-
translation modification in failing myocardium, important during cardiac stunning and in 
remodelled non-infarcted heart. Isometric force and ATPase activity measurements were 
performed in skinned human cardiac trabeculae and muscle strips; force was measured in 
cardiac myofibrils and cardiomyocytes. The technique of troponin complex exchange was 
validated for human cardiomyocytes. To establish the link between altered protein 
composition and functional properties of cardiac tissue analysis of contractile protein 
composition was performed using one-dimensional SDS polyacrylamide gel electrophoresis 
and Western immunoblot analysis. 
The questions addressed in this thesis are important to obtain insight into the 
cellular pathomechanisms of depressed contractility in human heart failure. This 
information will be important for the development of new targeted therapeutic interventions 
for the treatment of heart failure in the future. 
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The outline of this thesis is as follows: 
In Chapter 2, the functional and morphological differences between human non-
failing (donor) atrial and ventricular tissue were determined. In addition, it was investigated 
to what extent MHC isoform composition determines human myocardial performance using 
the variability present in MHC composition in atrial tissue. In Chapter 3, the functional 
properties and MHC isoform composition in both healthy and diseased ventricular and 
atrial human tissue were investigated to determine the functional relevance of relatively 
small changes in MHC isoform composition in failing human tissue. In Chapter 4, the 
functional consequences of C-terminal cTnI degradation in human cardiac myofibrils and 
cardiomyocytes were assessed. In Chapter 5, the changes in responsiveness to protein 
kinase A phosphorylation and to increasing sarcomere length of human cardiac 
myofilaments induced by cTnI proteolysis were studied to determine the effect of cTnI 
degradation on the β-adrenergic and preload-dependent responses. In Chapter 6, a 
summary of the major findings of the studies presented in this thesis and future research 
directions are presented. 
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Abstract 
Cardiac energetics and performance depend on the expression level of the fast (α-) and 
slow (β-) myosin heavy chain (MHC) isoform. In ventricular tissue the β-MHC isoform 
predominates, whereas in atrial tissue a variable mixture of α- and β-MHC is found. In 
several cardiac diseases the slow isoform is upregulated, however, the functional 
implications of this transition in human myocardium are largely unknown. The aim of this 
study was to determine the relation between contractile properties and MHC isoform 
composition in healthy human myocardium using the diversity in atrial tissue. Isometric 
force production and ATP consumption were measured in chemically skinned atrial 
trabeculae and ventricular muscle strips, and rate of force redevelopment was studied using 
single cardiomyocytes. MHC isoform composition was determined by one-dimensional 
SDS-gel electrophoresis. Force development in ventricular tissue was about 5-fold more 
economical, but 9 times slower, than in atrial tissue. Significant linear correlations were 
found between MHC isoform composition, ATP consumption and rate of force 
redevelopment. These results clearly indicate that even a minor shift in MHC isoform 
expression has considerable impact on cardiac performance in human tissue. 
 
 
Introduction 
The contractile protein myosin consists of two heavy chains (MHC), which contain the 
actin- and ATP-binding sites, and two pairs of light chains (MLC). The motor function of 
myosin is performed by MHC, while the MLCs exert a regulatory role.23,55,56 Two different 
isoforms of MHC (α and β) are expressed in mammalian cardiac muscle. Although they 
have 93% sequence homology,57 animal studies indicated that these isoforms possess 
distinct functional properties.58,59 Studies on rat and rabbit tissue indicated that the fast α-
MHC isoform exhibits a two to three times higher actin-activated ATPase activity58 and 
actin filament sliding velocity59 than the slow β-MHC isoform. 
In human myocardium the β-MHC predominates in ventricles, whereas a variable 
mixture of α- and β-MHC is found in atria. During human heart failure the α-MHC fraction 
declines in both atria and ventricles.21,34 However, the functional implications of this MHC 
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switch in human hearts are still unclear. Moreover, little is known about differences in 
contractile features and energy consumption between atrial and ventricular tissues. 
Thus, the first aim of the present study was to determine functional differences 
between human atrial and ventricular tissue. The second aim was to determine to what 
extent MHC protein composition determines human myocardial performance using the 
variability found in MHC composition in atrial tissue. Isometric force production, ATP 
utilisation and their Ca2+-sensitivities were measured in chemically skinned atrial trabeculae 
and ventricular muscle strips from human hearts. The main advantage of skinned 
preparations is that they allow standardisation of the conditions (e.g. composition of 
intracellular milieu and sarcomere length) under which functional properties are studied. 
Moreover, simultaneous measurement of force and ATP consumption in skinned 
myocardial tissue allows unambiguous determination of the relation between contractile 
and energetic properties. The rate of force redevelopment was recorded in single Triton-
skinned cardiomyocytes in order to obtain information on the kinetic properties of the 
actomyosin interaction. The MHC composition of the human atrial and ventricular biopsies 
was determined by one-dimensional gel electrophoresis and correlated with the functional 
properties measured in tissue from the same hearts. 
 
 
Methods 
Preparations 
Trabeculae were isolated from right atrial appendages obtained during coronary bypass 
surgery on patients (n=14; age 41-80 years) with normal left ventricular function. 
Ventricular muscle strips were isolated from left ventricular biopsies, which were obtained 
from healthy donor hearts (n=6; age 23-54 years) that could not be transplanted due to 
technical reasons, and were stored in liquid nitrogen. Samples were obtained after informed 
consent and with approval of the local ethics committees. The investigation conforms with 
the principles outlined in the Declaration of Helsinki. 20 atrial trabeculae and 13 ventricular 
strips were isolated in cold relaxing solution (pH 7.0; in mmol/l: free Mg2+ 1, KCl 145, 
EGTA 2, ATP 4, imidazole 10) and then chemically skinned in relaxing solution with 1% 
Triton X-100 overnight (4°C). Ventricular muscle strips were cut longitudinally, i.e. in 
parallel to the long axis of the cardiomyocytes in order to minimize damage. Mean 
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dimensions (± S.E.M.) of the atrial and ventricular preparations amounted to 1.61±0.12 and 
2.36±0.17 mm in length, 435±25 and 472±41 μm in width, and 384±22 and 495±34 μm in 
depth, respectively. Part of the biopsy was used for mechanical isolation of single 
cardiomyocytes as described previously.40,60 Before mechanical isolation, tissue was 
defrosted in relaxing solution. During the isolation the tissue was kept on ice. Tissue 
samples were mechanically disrupted within a few seconds in relaxing solution using a 
small glass tissue homogeniser. Isolated myocytes were immersed for 5 minutes in relaxing 
solution containing 0.5% Triton X-100. To remove the Triton, cells were washed twice in 
relaxing solution. Thereafter, a single myocyte was attached between a force transducer and 
a piezoelectronic motor. The remainder of the biopsy was used for determination of MHC 
composition. 
 
MHC composition  
MHC composition was analysed by one-dimensional SDS-gel electrophoresis (1D SDS-
PAGE), silver staining and laser scanning densitometry as described by van der Velden et 
al.40,61 1D SDS-PAGE was performed using an acrylamide to bis-acrylamide ratio of 200:1 
in the separating gel (12% acrylamide; pH 9.3) and of 20:1 in the stacking gel (3.5% 
acrylamide; pH 6.8). Densitometric analysis was performed on a LKB UltroScan XL 
Enhanced Laser Densitometer (LKB Produkter AB, Bromma, Sweden) using the GelScan 
XL software package (Pharmacia, Uppsala, Sweden). To check for linearity, different 
amounts of atrial and ventricular tissue (0.2-1.0 μg) were loaded and the density of the 
MHC bands was analysed. Based on these determinations 0.5 μg was chosen for sample 
application as it was found to be within the linear range. In one ventricular sample, 
containing a relatively small amount of the α-MHC isoform (Figure 2.1C), the intensity 
profile was fit to the sum of 2 Gaussian curves representing the α- and β-isoforms and the 
ratio was calculated from the area underneath the α-peak divided by the total MHC area. 
For validation of MHC isoform analysis various mixtures (3:1, 1:1, 1:3) of an atrial (84.7% 
α-MHC) and a ventricular (99.3% β-MHC) tissue sample were applied. The percentage of 
β-MHC obtained from the densitometric analysis correlated well with the amount of 
ventricular sample present in the mixture (r2=0.97, Figure 2.1A). Since the distance on gel 
between α- and β-MHC bands is increased by using less total acrylamide a comparison was 
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made between 8% SDS-PAGE21,34 and 12% SDS-PAGE.40,61 No significant differences 
were found between the data obtained with the two gel protocols. 
 
Measurements of force, ATP consumption and rate of force redevelopment 
The experimental procedures and equipment used were as described previously.62,63 
ATPase activity was measured by enzymatic coupling of ATP resynthesis to the oxidation 
of NADH, which could be quantified photometrically from the absorbance of near-UV 
light. The composition of relaxing, preactivating and activating solutions was calculated as 
described recently.64 Isometric force and ATPase activity were measured at saturating and 
subsaturating Ca2+ concentrations at 20±1°C. Maximum force was determined when a 
steady-state force was reached. In a few ventricular preparations the force values reached 
after approximately 3 minutes of activation were used as maximal values. On average force 
decline between the first and the last maximal control activation amounted to 18±1 and 
10±2% for atrial and ventricular preparations, respectively. The Ca2+-activated ATPase 
activity was determined by subtraction of basal ATPase activity (measured in relaxing 
solution) from total ATPase activity measured in activating solution with various Ca2+ 
concentrations. The length of the preparations was adjusted on the basis of passive tension 
by stretching them to 1-2 kN/m2. In two trabeculae it was possible to examine sarcomere 
length by means of laser diffraction. The sarcomere lengths found after adjustment of the 
length of the preparations amounted to 2.20 and 2.15 μm. This corresponds well with the 
values found by Kentish et al.65 in rat trabeculae. The cross-sectional area of the 
preparations was estimated assuming an elliptical shape, i.e. cross-sectional area = (width × 
depth × π)/ 4. 
The rate of force redevelopment was determined at saturating Ca2+ concentration 
in Triton-skinned single cardiomyocytes at 15±1°C.63 In brief, when reaching a steady level 
of force the myocyte was rapidly shortened and after a delay of 30 ms, restretched by 20% 
of its length. Upon shortening force dropped to zero and upon restretch force 
redevelopment occurred to the initial steady level. Force redevelopment was fitted to a 
single exponential to estimate the rate of force redevelopment (KTR). 
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Histochemical analysis 
Histochemical analysis was performed on 6 atrial trabeculae and 5 ventricular preparations. 
At the end of the experiment preparations were embedded in relaxing solution containing 
15% (w/v) gelatin and frozen in liquid nitrogen. Tissue sections (5 μm) were cut with a 
cryostat (Leica CM 1850, Rijswijk ZH, Netherlands) at -22°C. Sections were collected on 
slides treated with Vectabond (Vector Laboratories, Burlingame, CA), air dried for 20 min 
and slides were stored at –80°C. The sections were fixed at room temperature for 5 min in a 
4% formalin in 0.1 M phosphate buffer, pH 7.4. After hematoxylin and eosin staining, the 
sections were dehydrated and mounted in Entallan (Merck, Darmstadt, Germany). Sections 
were studied as described previously66 using a Leica DMRB microscope (Wetzlar, 
Germany). Images were collected with a Sony XC-77CE camera (Towada, Japan) 
connected to a LG-3 frame grabber (Scion, Frederick, MD, USA) on personal computer, 
and analysed using public domain software (NIH Image 1.61). The myofibrillar area and 
interstitial space were determined relative to the cross-sectional area and expressed as 
percentages. 
 
Data analysis 
Force-pCa and ATPase-pCa relations were fit by a non-linear fit procedure to a Hill 
equation:67 
 F(Ca2+)/F0=[Ca2+]nH/(Ca50nH +[Ca2+]nH), 
where F is steady state force (or ATPase activity). F0 denotes the steady force (or ATPase 
activity) at saturating Ca2+ concentration, nH reflects the steepness of the relation, and Ca50 
(or pCa50) represents the midpoint of the relation. 
All data were averaged per patient. Values are given as means ± S.E.M. of n 
patients. All statistical statements are based on two tailed Student’s t-tests with a 0.05 level 
of significance. 
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Results 
MHC composition 
MHC isoforms were separated using 1D SDS-PAGE (Figure 2.1). Densitometric analysis 
of the SDS-gels (Figure 2.1C) revealed that atrial tissue consisted of a variable mixture of 
α- and β-MHC (β-MHC ranged from 6.9 to 51.3% of total MHC content), while β-MHC 
was the predominant isoform in ventricular tissue (Table 2.1). In two of the ventricular 
samples low expression levels of α-MHC were detected. Low abundance in these two 
samples was confirmed by Western immunoblotting. Western immunoblotting, performed 
on all ventricular samples using a specific monoclonal antibody against α-MHC,40 yielded 
negative results except in these two samples. 
 
 
Figure 2.1. MHC composition in 
atrial and ventricular tissue. A. 
Validation of MHC analysis by SDS-
PAGE using various mixtures (3:1, 1:1 
and 1:3) of an atrial (84.7% α-MHC) 
and a ventricular (99.3% β-MHC) 
tissue sample. The percentage of β-
MHC obtained from the densitometric 
analysis correlated well with the 
amount of ventricular sample present in 
the mixture. Regression line: β-MHC 
(in %) = (21.3±4.9) + (0.78±0.08) × 
ventricular tissue sample portion (in %) 
(r2=0.97, P<0.05). B. Silver stained 
SDS-polyacrylamide gel of MHC 
proteins in an atrial (A) and a 
ventricular (V) tissue sample. C. Laser 
densitometric scan corresponding to 
the atrial (A) and ventricular (V) 
samples shown in Figure 2.1B. AU, 
arbitrary units. 
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Table 2.1. Mean parameters in atrial and ventricular tissue 
Parameter Atrial (n=14) Ventricular (n=6) 
β-myosin heavy chain content (% of total 
MHC) 
24.6±3.2 94.7±5.2* 
Ca2+-activated ATPase activity per 
preparation volume (mmol⋅l-1⋅s-1) 
0.147±0.015 0.045±0.007* 
Basal ATPase activity at pCa 9 (% of total) 11±1 11±1 
Maximal tension (kN·m-2) 13.7±1.0 18.6±2.3* 
pCa50 force 5.68±0.04 5.67±0.04 
nH force 2.70±0.17 2.29±0.29 
pCa50 ATPase activity 5.69±0.04 5.68±0.04 
nH ATPase activity 2.33±0.14 2.36±0.35 
Tension cost (mmol·kN-1⋅m-1⋅s-1) 11.4±1.4 2.4±0.3* 
Maximal KTR (s-1) 7.76±1.54 0.87±0.06* 
Myofibrillar tissue (%) 50±9 89±2* 
Interstitial space (%) 20±4 11±2 
Maximal tension corrected for myofibrillar 
tissue (kN·m-2) 
32.8±8.5 21.1±2.1 
Ca2+-activated ATPase activity per 
preparation volume corrected for 
myofibrillar tissue (mmol⋅l-1⋅s-1) 
0.260±0.025 0.051±0.011* 
 
Abbreviations: pCa = -log [Ca2+]. pCa50, Ca2+ concentration at which half of the maximal isometric force or ATPase activity is 
obtained; nH, steepness of pCa-force and pCa-ATPase activity relationships. Values are given as mean ± S.E.M. of n patients. 
Myofibrillar tissue and interstitial space were determined for 6 and 5 preparations of atrial and ventricular tissue, respectively. 
*significant at P<0.05, atrial versus ventricular. 
 
Functional properties 
Recordings of isometric force and ATP consumption in an atrial trabecula and a ventricular 
muscle strip during a contraction-relaxation cycle at saturating Ca2+ concentration are 
shown in Figure 2.2A and B. The slope of the regression line fitted to the NADH 
absorbance signal (Figure 2.2B) was considerably steeper in atrial than in ventricular 
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preparations. Indeed, the maximal rate of Ca2+ activated ATP consumption (i.e. ATPase 
activity per preparation volume) was on average 3.3 times larger in atrial tissue than in 
ventricular tissue (0.147±0.015 and 0.045±0.007 mmol⋅l-1⋅s-1, respectively). Maximal 
isometric tension (i.e. force divided by cross-sectional area) was lower in atrial trabeculae 
than in ventricular muscle strips. Table 2.1 provides mean values of Ca2+-sensitivity (pCa50) 
and steepness of the relationships (nH) of both force and ATP consumption. No significant 
difference was found in these parameters between atrial and ventricular preparations. 
Representative examples of force-pCa and ATPase activity-pCa curves obtained in one 
atrial trabecula are shown in Figure 2.3. 
 
       
Figure 2.2. Recordings of force and NADH absorbance in an atrial trabecula and a ventricular strip 
during a contraction-relaxation cycle. A. Force production and B. NADH absorbance recorded at 
saturating Ca2+ concentration. When the preparation was transferred to the activating solution, isometric 
force developed and the NADH absorbance signal started to decline. ATP consumption was determined by 
calculation of the slope of the dotted regression line fitted to the absorbance signal during the last 20 
seconds of activation. After returning trabeculae into the relaxing solution 0.5 nmol ADP was injected into 
the measuring bath to calibrate the absorbance signal. The zero level of the absorbance signal was arbitrarily 
chosen. Dimensions of the preparations were 2.5 mm in length, 420 μm in width and 380 μm in depth for 
atrial and 2.7 mm in length, 480 μm in width and 507 μm in depth for ventricular. 
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Figure 2.3. Ca2+-sensitivity of isometric force and ATPase activity. The force-pCa and ATPase activity-
pCa relation of an atrial trabecula from one atrial biopsy are shown as representative examples. Isometric 
force and ATP utilisation rate at submaximally activating Ca2+ concentrations are normalised to the control 
force/ATP utilization rate found at saturating Ca2+ concentration (pCa 4.5). Both the force-pCa and ATPase 
activity-pCa relations were fitted to a Hill equation. 
 
 
 
         
 
Figure 2.4. Correlation between KTR and ATPase activity. A linear relationship exists between the rate of 
force redevelopment and mean ATPase activity (n=12 for atria and n=6 for ventricles). Regression line: 
ATPase activity/volume (in mmol⋅l-1⋅s-1) = (0.07±0.02) + (0.008±0.003)× KTR (in s-1) (r2=0.35, P<0.05). 
KTR (s-1) 
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Tension cost was calculated for each preparation by dividing ATP consumption per 
preparation volume by force per cross-sectional area. The preparation volume equals cross-
sectional area multiplied by preparation length. Therefore, this measure has the advantage 
that it is independent of possible inaccuracy in the determination of cross-sectional area of 
the preparation. Tension cost is a measure of muscle economy, i.e. the rate of ATP splitting 
necessary for maintenance of isometric force. Tension cost (in mmol⋅kN-1⋅m-1⋅s-1) amounted 
to 11.4±1.4 in atrial tissue and to 2.4±0.3 in ventricular tissue. This implies that the 
economy of force maintenance in ventricular tissue is about 5 times larger than in atrial 
tissue. 
The rate of force redevelopment (KTR) measured in single isolated cardiomyocytes 
was on average 9 times higher in atrial than in ventricular tissue. These values are also 
summarized in Table 2.1. When ATPase activity was plotted as a function of KTR (Figure 
2.4) a weak but significant linear correlation was found between these two parameters 
(r2=0.35; P<0.05). 
 
Correlation between MHC content and functional properties 
Significant linear correlations were found between maximal isometric force, rate of ATP 
consumption, tension cost and MHC composition (Figure 2.5). The rate of ATP 
consumption of preparations with pure (100%) α-MHC (estimated by extrapolation of the 
regression line) was approximately 5 times higher than the rate of preparations with pure β-
MHC (0.181±0.018 and 0.039±0.014 mmol⋅l-1⋅s-1, respectively, for extrapolated values ± 
their standard errors). In addition, a significant negative correlation was found between 
mean KTR and β-MHC content (r2=0.55) (Figure 2.6). The KTR associated with pure α-
MHC expression calculated from the regression line (10.76 s-1) was considerably higher 
than the values obtained in ventricular tissue (0.87 s-1). 
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Figure 2.5. Correlations between β-MHC content and isometric force, ATP consumption and tension 
cost. A. Isometric force per cross-sectional area averaged per every patient (n=14 for atria and n=6 for 
ventricles) depended significantly on β-MHC composition. Regression line: isometric force/cross-sectional 
area (in kN⋅m-2) = (12.2±1.7) + (0.07±0.03)× β-MHC (in %) (r2=0.22, P<0.05). B. A significant negative 
correlation exists between β-MHC fraction (% of total MHC) and mean ATPase activity for every patient 
(n=14 for atria and n=6 for ventricles). Regression line: ATPase activity/volume (in mmol⋅l-1⋅s-1) = 
(0.18±0.02) – (0.0014±0.0003)× β-MHC (in %) (r2=0.54, P<0.05). C. A significant correlation was also 
found between β-MHC content and mean tension cost for every patient (n=14 for atria and n=6 for 
ventricles). Regression line: Tension cost (in mmol·kN-1⋅m-1⋅s-1) = (14.32±1.62) – (0.124±0.028)× β-MHC 
(in %) (r2=0.51, P<0.05).  
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Myofibrillar density 
Histochemical analysis revealed that the average density of myofibrillar tissue was 
significantly lower in atrial (Figure 2.7A, C) than in ventricular (Figure 2.7B, D) 
preparations (50±9 and 89±2%, respectively, Table 2.1), mainly because in atrial tissue an 
outer layer of connective tissue was found and occasionally blood vessels were present 
(Figure 2.7A). The difference in the percentage of interstitial space in atrial (20±4%) and 
ventricular (11±2%) tissue did not reach statistical significance (P=0.09; Table 2.1). 
The overall difference in amount of myofibrillar tissue between atrial and 
ventricular preparations may explain part of the differences in isometric force and ATP 
consumption between atrial and ventricular tissue. To investigate this point, data were 
corrected for the proportion of myofibrillar tissue. It abolished the difference in maximal 
tension, increased the difference in ATPase activity and slightly enhanced the relative 
difference in the extrapolated ATPase-values of the “pure” isoforms (Table 2.1). These 
results suggest that the difference in maximal isometric force found between atrial and 
ventricular preparations was due to the difference in the amount of myofibrillar tissue. 
Within the preparations used for histochemical analysis (n=11) no correlation was present 
between maximal force and MHC composition both before and after correction of the data 
for the proportion of myofibrillar tissue (Figure 2.8A). However, the correction slightly 
improved the correlation between ATPase activity and β-MHC composition as reflected by 
an increase in the r2 value from 0.72 for the uncorrected data to 0.79 for the corrected data 
(Figure 2.8B), but, as expected, it did not influence the values obtained for tension cost. 
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Figure 2.7. Cross-sectional images of preparations. Cross-sectional images of an atrial trabecula (A, C) 
and ventricular muscle strip (B, D) were made at 10x (A, B) and 40x (C, D) magnification. Atrial trabeculae 
have a surrounding layer of connective tissue and occasionally contain blood vessel(s). The atrial trabecula 
shown in panel A contains one blood vessel. Dark red structures correspond to myofibrillar tissue, while 
lighter parts correspond to the non-myofibrillar tissue. 
Figure 2.6. Correlations between β-MHC content and 
rate of force redevelopment (KTR). A significant 
correlation exists between β-MHC content and mean KTR 
for every patient (n=12 for atria and n=6 for ventricles). 
Regression line: KTR (in s-1) = (10.76±1.49) – 
(0.111±0.025)× β-MHC (in %) (r2=0.55, P<0.05). 
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Figure 2.8. Correction of data for the amount of myofibrillar tissue. The correction of isometric force 
per cross-sectional area (A) and ATPase activity per volume (B) was performed in 6 atrial (open symbols) 
and 5 ventricular (closed symbols) preparations and the regression lines to the uncorrected (continuous line, 
circles) and corrected data (dotted line, squares) are shown. Isometric force did not depend on β-MHC 
composition for both uncorrected and corrected data. Regression line of uncorrected values: isometric 
force/cross-sectional area (in kN⋅m-2) = (16.8±3.5) + (0.03±0.05)× β-MHC (in %) (r2=0.04, P=0.57). 
Regression line of corrected values: isometric force/cross-sectional area (in kN⋅m-2) = (45.1±10.3) - 
(0.2±0.1)× β-MHC (in %) (r2=0.18, P=0.20). Correction enhanced the correlation between β-MHC 
composition and ATPase activity. Regression line of uncorrected values: ATPase activity/volume (in 
mmol⋅l-1⋅s-1) = (0.19±0.02) – (0.0015±0.0003)× β-MHC (in %) (r2=0.72, P<0.05). Regression line of 
corrected values: ATPase activity/volume (in mmol⋅l-1⋅s-1) = (0.38±0.04) – (0.0032±0.0006)× β-MHC (in 
%) (r2=0.79, P<0.05). 
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Discussion 
This study shows that force development in human ventricular tissue is about 5 times more 
economical, though 9 times slower than in atrial myocardium and provides evidence that 
these differences are largely attributable to the difference in myosin heavy chain isoform 
composition. Significant linear relations were found between the MHC composition and 
ATP consumption and rate of force redevelopment. Extrapolation of these relations 
indicated that ATP consumption of the pure α-MHC was 5 times higher, whereas force 
redevelopment was considerably faster than observed for the β-MHC. It should be noted, 
however, that the extrapolated values have to be considered with caution because the scatter 
in the data is rather high. In addition, the linear relations used for the data analysis 
implicitly imply that myosin molecules act as independent force generators. Evidence 
suggests that this might not necessarily be the case.59,68 However, even if interaction 
between myosin heads does occur the functional differences between atrial and ventricular 
tissue would remain. In fact, the concave relationships found59,68 would imply that the 
difference between the properties of the pure isoforms would become even larger. Within 
atrial tissue, the correlation between MHC composition and rate of force redevelopment 
was significant (r2=54, P<0.05), and although the correlation between MHC composition 
and ATP consumption for atrial samples did not reach statistical significance (P=0.18), its 
functional relation was rather similar to the relationship found for the combined set of atrial 
and ventricular data. 
 
Methodological considerations 
It should be noted that isometric force and ATP consumption were determined at 20°C, 
whereas KTR values were determined in cardiac myocytes at 15°C. These experimental 
temperatures were chosen to facilitate comparison with previous studies in rat and human, 
from which it also became apparent that at higher temperatures sarcomere uniformity and 
stability of the cardiomyocytes during the measurements were not well preserved. We do 
not expect a difference in temperature dependency of functional properties between atrial 
and ventricular tissue, but caution should be exerted in extrapolation of the values found in 
this study to body temperature. 
During activation inorganic phosphate (Pi) accumulates in the preparations due to 
the ATP hydrolysis. Since Pi accumulation is proportional to the ATPase activity and the 
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square of muscle diameter, this accumulation will be approximately 0.17 and 0.70 mM 
respectively in the ventricular and atrial preparations used in this study. From the previous 
studies in rat69 and human cardiac myocytes22,67 it followed that such low amounts of Pi 
depress force by less than 5%, while the effect on ATPase activity will be even smaller. 
Since, Pi accumulation is somewhat larger in atrial than in ventricular tissue, it slightly 
reduces the difference in force and consequently, in tension cost between atrial and 
ventricular tissue. However, overall the impact of Pi accumulation on functional properties 
is very minor and therefore does not affect the conclusions of this study. 
 
Ca2+-sensitivity  
The Ca2+-sensitivities of force and ATPase activity observed both in atrial and in 
ventricular tissue were very similar (Table 2.1). This indicates that the difference in tension 
cost between atrial and ventricular tissue is independent of the free Ca2+ concentration and 
implies that the energetic differences observed also hold at sub-maximal Ca2+ 
concentrations found in vivo. 
 
Effect of MHC composition 
During human heart failure a shift has been observed from the fast α-MHC isoform to the 
slow β-MHC isoform both in atria and ventricles.21,34 The marked difference in economy 
observed in this study, clearly indicates that even a minor shift is associated with an 
improvement of the economy of contraction, albeit at the expense of speed of force 
development. It can be calculated from our experiments that a 7% decline in α-MHC 
composition, as was found in failing human ventricles by Miyata et al.,34 will cause a 20% 
reduction in maximal ATPase activity. Recently, it has been shown that expression of a 
small amount of α-MHC (~12%) in rat cardiomyocytes significantly increases power 
output,70 whereas no significant differences in isometric force or actin sliding velocity were 
observed between nonfailing and failing human myosin with a minor (~3%) difference in 
the expression of fast myosin (V1).71 Our results in human tissue are in line with the 
observations in rat cardiomyocytes70 and suggest that enhanced economy is paralleled by a 
reduction in maximum power output. 
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Effect of regulatory proteins and their phosphorylation status 
Although the catalytic subdomain of ATPase activity and the actin binding region are 
located at the head portion of myosin, other contractile proteins, such as the myosin light 
chains and the troponin complex may exert a modulatory role in contraction.23,40,52,56,72-74 
Part of the variability in contractile properties within and between atrial and ventricular 
tissue may be explained by the expression of tissue-specific isoforms and/or by differences 
in phosphorylation status of contractile proteins. For instance, protein kinase C mediated 
phosphorylation of troponin has been shown to reduce both maximum tension and 
actomyosin Mg-ATPase activity by ~30% in mouse myocardium.52,73,74 It should be noted 
that these effects are relatively small compared to the 3.3-fold difference in ATPase activity 
between atrial and ventricular tissue. Moreover, if troponin phosphorylation induces a 
parallel change in force and ATPase activity, it would not affect the differences in economy 
observed in the present study. 
 
Speed versus economy 
The correlation between ATPase activity and KTR (Figure 2.4) resembles previous 
observations on stable maintenance heat rate and rate of force redevelopment in skeletal 
muscle fibers.75 In a simple 2-state model for crossbridge interaction28 ATPase activity is 
governed by the rate limiting step in the crossbridge cycle: the rate of crossbridge 
detachment (g) and KTR = f + g, where f equals the rate of crossbridge attachment. The 
proportionality observed between ATPase activity and KTR thus suggests that either KTR is 
dominated by g (f>>g) or that f and g covary in proportion in different mixtures of fast and 
slow cardiac MHC isoforms (i.e. f = c·g; where c is constant). In either case maximal 
tension, which is proportional to f / (f + g), would be expected to be similar in atrial and 
ventricular preparations, as was found experimentally after correction for myofibrillar 
tissue density (Table 2.1). 
Cardiac adaptation to mechanical overload is likely governed by the trade-off 
between speed and economy of contraction.76,77 This principle might also explain why the 
relatively “expensive” fast MHC-isoform predominates in the atria: the contribution of 
atrial contraction to ventricular filling is rather small (as are the associated energy costs) but 
it might gain importance, and promote cardiac output, at high heart rate. Moreover, it is 
noteworthy that in states of reduced ventricular compliance such as ventricular hypertrophy 
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and heart failure the atrial contribution to ventricular filling increases by approximately 
20%.78 
 
Conclusion 
Since our data show that the slow isoform is 5 times more economical than the fast isoform, 
the switch towards the slow β isoform clearly has considerable impact on performance in 
human atrial and ventricular myocardium. 
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Abstract 
Changes in myosin heavy chain (MHC) isoform expression and protein composition occur 
during cardiac disease and it has been suggested that even a minor shift in MHC 
composition may exert a considerable effect on myocardial energetics and performance. 
Here an overview is provided of the cellular basis of the energy utilization in cardiac tissue 
and novel data are presented concerning the economy of myocardial contraction in diseased 
atrial and ventricular human myocardium. ATP utilisation and force development were 
measured at various Ca2+ concentrations during isometric contraction in chemically skinned 
atrial trabeculae from patients in sinus rhythm (SR) or with chronic atrial fibrillation (AF) 
and in ventricular muscle strips from non-failing donor or end-stage failing hearts. 
Contractile protein composition was analysed by one-dimensional gel electrophoresis. 
Atrial fibrillation was accompanied by a significant shift from the fast α-MHC isoform to 
the slow β-MHC isoform, whereas both donor and failing ventricular tissue contained 
almost exclusively the β-MHC isoform. Simultaneous measurements of force and ATP 
utilisation indicated that economy of contraction is preserved in atrial fibrillation and in 
end-stage human heart failure. 
 
 
Introduction 
Human cardiac tissue contains 2 isoforms of the myosin heavy chain (MHC): fast (α-) and 
slow (β-) MHC, which share 93% of structural homology in the rat.57 Functional properties 
of these two isoforms have been studied mainly in rodent tissue. For instance, it was found 
in rat and rabbit ventricular tissue that the α-MHC isoform exhibits a two to three times 
higher actin-activated ATPase activity58 and actin filament sliding velocity59 than the β-
MHC isoform. Recently, in experiments on skinned human atrial and ventricular 
preparations we found that the β-MHC isoform is approximately 5 times more economical, 
but considerably slower than the α-MHC isoform.79 Comparable observations were 
obtained in rodent models.61,80,81 
In many forms of cardiac disease resulting in pressure or volume overload of the 
heart as well as with aging, a transition from α- to β-MHC takes place.61,82 This could be 
advantageous, since less energy is required for force maintenance, but a shift towards more 
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β-MHC also reduces the speed of contraction and relaxation.83,84 This compromises 
diastolic function of the ventricles at higher heart rates. Moreover, the contribution of the 
atrial contraction to filling of the ventricle may be reduced by alterations in the timing of 
the contractions. For instance, a recent study in transgenic mice showed that a shift is 
disadvantageous under severe cardiovascular stress.85 
Interestingly, similar examples of muscle plasticity are found in skeletal muscle: 
aging, immobilization, bed-rest and microgravity are all associated with a shift in the MHC 
distribution from slow to fast isomyosins.86-89 In addition, our group recently found in 
skeletal muscle fibres from patients with chronic heart failure evidence for a marked almost 
2-fold reduction in force development and ATP utilisation in comparison with fibres of the 
same type from healthy age-matched control subjects.90 This latter observation suggests 
that apart from a shift in MHC isoforms, also structural and posttranslational modifications 
may occur in skeletal muscle. Posttranslational modifications, such as altered 
phosphorylation, are prominent in diseased myocardium and influence contractile 
function.40,63,91,92 
In the heart differences are observed in the MHC isoform composition of the atria 
and the ventricles, which are age and species dependent.61,93-96 The general tendency is that 
with an increase in body size and age the expression of the slow β-MHC isoform becomes 
more pronounced. In addition, in human atrial tissue, an approximately one-to-one ratio is 
found between the fast and slow MHC isoforms, whereas in the ventricles the slow MHC 
isoform predominates. Evidence that an age-dependent shift may be operative in human 
ventricles has been obtained recently.97 In addition, regional expression patterns in the 
regulatory myosin light chain are evident in diseased ventricular tissue,98 which may also 
have functional implications. 
The expression patterns also vary with cardiac hypertrophy (e.g.99). It has been 
shown in human ventricular tissue that the proportion of α-MHC mRNA of total MHC 
mRNA was ~30% in non-failing and was reduced to ~2% in end-stage failing hearts.100,101 
This group of investigators also showed that the efficiency of translational regulation is 
variable: in 12 non-failing hearts 35% of α-MHC mRNA was present, but only 7% α-MHC 
protein was expressed, similarly, in end-stage failing hearts, despite of the presence of a 
low amount of α-MHC mRNA, no α-MHC protein was detected.34 
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An important question is whether the relatively small changes in MHC 
composition in human tissue have functional relevance. From the difference in the 
maximum shortening velocity of the fast and slow isoforms and because of the usually 
observed increased steepness of the force-velocity relation in slow myosins, we 
hypothesized that power output, the mathematical product of force and velocity, might vary 
strongly with even small shifts in MHC composition. Evidence in favour of this was 
obtained in rat cardiac tissue.70 Therefore, we investigated functional properties and 
contractile protein composition in both healthy and diseased human ventricular and atrial 
tissue. Muscle strips were isolated from ventricular donor and failing explanted hearts and 
trabeculae were excised from atrial biopsies obtained during bypass and valve surgery of 
patients in sinus rhythm and chronic atrial fibrillation. ATPase activity and isometric force 
development were measured simultaneously in these preparations at various Ca2+ 
concentrations. 
 
 
Materials and methods 
Biopsies 
Atrial samples were obtained from right atrial appendages during coronary bypass and 
valve replacement surgery on patients with sinus rhythm (SR) (n=15; age 60±3 years) and 
normal left ventricular function and patients with chronic atrial fibrillation (AF) (n=12; age 
69±3 years), who had moderate or bad left ventricular function. Duration of atrial 
fibrillation was ≥ 3 months. 
Left ventricular biopsies were obtained during heart transplantation surgery from 6 
non-failing donor hearts (age 41±5 years) and 6 explanted end-stage failing (New York 
Heart Association class IV) hearts (55±4 years). Heart failure resulted from ischemic (n=5) 
or dilated (n=1) cardiomyopathy. Biopsies were divided in two parts: one part was used for 
protein analysis, and the other part was used to isolate preparations for subsequent 
isometric force and ATP consumption measurements. Samples were obtained after 
informed consent and with approval of the local ethical committees. The investigation 
conformed with the principles outlined in the Declaration of Helsinki. Clinical 
characteristics of the patients are presented in Table 3.1. 
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Table 3.1. Clinical characteristics of patients 
# Gender NYHA class Operation/Disease Medication 
ATRIAL 
SR  
1 M II/III CABG Asa, β, Ca2+ ant , nitr, stat 
2 M III AVR Asa, β, nitr, stat 
3 F I/II AVR - 
4 M III CABG Asa, ACE, nitr, diur, stat 
5 F IV CABG Asa, ACE, β, Ca2+ ant, stat 
6 M IV CABG Asa, β, nitr, stat 
7 M II/III CABG Asa, β, Ca2+ ant, ATII ant, stat 
8 M II CABG, I ACE, Ac, β  
9 M II/III CABG Asa, β, nitr, stat 
10 M II CABG Asa, β, nitr, stat 
11 M IV CABG Asa, β, Ca2+ ant, nitr, stat 
12 M II/III CABG, I Asa, β, stat 
13 M II CABG Asa, β, Ca2+ ant, nitr, stat 
14 M III CABG/AVR Asa, β, nitr 
15 M III CABG Asa, β, nitr, stat 
AF 
1 M III/IV CABG, I Ac, ACE, ATII ant,dig, stat 
2 M IV MVR Ac, ACE, dig, diur 
3 M III CABG Ac, β, dig, diur 
4 M IV MVR Ac, ACE, β, diur 
5 F III MVR Ac, ACE, β, dig, diur 
6 M III CABG, I Ac, ATII ant, β, diur 
7 M III CABG/AVR/MVR Ac, dig, diur, nitr 
8 M II CABG/AVR Ac, ACE 
9 F III CABG/AVR, DM Ac, ACE, Ad, dig, diur 
10 M II MVR/TVR Ac, dig, diur 
11 F III MVR/TVR Ac, ACE, β, diur 
12 M III CABG Asa, Ac, ACE, β, dig, diur 
VENTRICULAR 
D  
1 F - - - 
2 M - - - 
3 M - - - 
4 F - - - 
5 M - - - 
6 F - - - 
HF  
1 M IV DCM Ac, ACE, diur 
2 M IV ISCM Ac, ACE, diur, dig, PI 
3 M IV ISCM Ac, ACE, diur, nitr, PI 
4 F IV ISCM Ca2+ ant 
5 M IV ISCM Ac, ACE, diur, dig 
6 F IV ISCM Ac, ACE, diur, PI 
 
Abbreviations: SR: sinus rhythm, AF: atrial fibrillation, D: donor, HF: heart failing, M: male, F: female, AVR/MVR/TVR: atrial 
(mitral or tricuspid) valve replacement, CABG: coronary artery bypass grafting, DCM- dilated cardiomyopathy, ISCM- ischemic 
cardiomyopathy, DM: diabetes mellitus, I: old infarction. Medication: Ac: anticoagulants, ACE: ACE inhibitor, Ad: anti-diabetic, 
Asa: acetyl salicylic acid, ATII ant: ATII antagonist, β: beta blockers, Ca2+ ant: calcium antagonist, diur: diuretics, dig: digoxine, 
nitr: nitrates, PI : positive inotropic agent, stat: statine. 
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Protein analysis 
The myosin heavy chain isoform composition was analysed by one-dimensional SDS 
polyacrylamide gel electrophoresis (1D SDS-PAGE).40,61 The separating gel contained 12% 
total acrylamide (acrylamide to bis-acrylamide ratio 200:1; pH 9.3), while the stacking gel 
contained 3.5% total acrylamide (acrylamide to bis-acrylamide ratio 20:1; pH 6.8). Gels 
were stained with silver and analysed by laser densitometry. To check for linearity, 
different amounts of atrial and ventricular tissue (0.2-1.0 μg) were loaded and the density of 
the MHC bands was analysed. Based on these determinations 0.5 μg was chosen for sample 
application as it was found to be within the linear range. 
 
Isolation of atrial trabeculae and ventricular strips 
All preparations were isolated as described earlier.79 Briefly, 21 SR and 23 AF atrial 
trabeculae were isolated in cold relaxing solution (pH 7.0; in mmol/l: free Mg2+ 1, KCl 145, 
EGTA 2, ATP 4, imidazole 10). Ventricular muscle strips (13 donor and 16 failing) were 
dissected parallel to the long axis of the muscle cell orientation. The mean dimensions (± 
S.E.M.) of atrial trabeculae amounted to 1.61±0.11 and 1.50±0.13 mm in length, 431±24 
and 404±25 μm in width, and 380±22 and 373±25 μm in depth, for SR and AF group 
respectively. For ventricular donor and failing preparations mean dimensions were 2.36 
±0.17 and 2.17±0.23 mm in length, 472±41 and 398±33 μm in width, and 495±34 and 
374±23 μm in depth, respectively. After isolation, all preparations were chemically 
permeabilised in relaxing solution with 1% Triton X-100 overnight (4°C). Next, the 
preparation was mounted between a force transducer and a fixed hook by means of 
aluminium T-clips. 
 
Isometric force and ATP consumption measurements 
The experimental procedures and equipment used were as described previously.62,79 
ATPase activity was measured by enzymatic coupling of ATP resynthesis to the oxidation 
of NADH, which could be quantified photometrically from the absorbance of near-UV 
light. Standard relaxing, preactivating and activating solutions were used.64 The pCa (-
log10[Ca2+]) of the relaxing and maximally activating solution were, respectively, 9 and 4.5. 
Solutions with intermediate [Ca2+] were obtained by mixing of the activating and relaxing 
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solutions. Isometric force and ATPase activity were measured at 20±1°C. Maximum force 
and ATPase activity were determined when a steady-state force was reached. On average, 
force decline between the first and the last maximal control activation amounted to 18±1% 
and 20±2% for SR and AF atrial preparations, and to 10±2% and 8±3% for donor and 
failing ventricular preparations, respectively. The Ca2+-activated ATPase activity was 
determined by subtraction of basal rate of ATP utilisation (measured in relaxing solution) 
from total rate of ATP utilisation measured in activating solution with various Ca2+ 
concentrations. The length of the preparations was adjusted on the basis of passive tension 
by stretching them to 1-2 kN/m2, which corresponds to a sarcomere length of about 2.2 
μm.79 The cross-sectional area of the preparations was estimated assuming an elliptical 
shape. 
 
Histochemical analysis 
Histochemical analysis was performed as described previously.79 At the end of the 
experiment preparations were embedded in relaxing solution containing 15% (w/v) gelatine 
and frozen in liquid nitrogen. Tissue sections (5 μm) were cut and subsequently stained 
with hematoxylin and eosin. Afterwards the sections were studied as described by des 
Tombe et al.66 using a Leica DMRB microscope (Wetzlar, Germany). The myofibrillar area 
and interstitial space were determined relative to the cross-sectional area and expressed as 
percentages. 
 
Data analysis 
Force-pCa and ATPase-pCa relations were fit to a Hill equation:67 
 F(Ca2+)/F0=[Ca2+]nH/(Ca50nH +[Ca2+]nH),  
where F is steady state force (or ATPase activity). F0 denotes the steady force (or ATPase 
activity) at saturating Ca2+ concentration, nH reflects the steepness of the relation, and Ca50 
(or pCa50) represents the midpoint of the relation. 
All data were averaged per patient. Values are given as means ± S.E.M. of n 
patients. All statistical statements are based on two tailed Student’s t-tests with a 0.05 level 
of significance. Linear regression analysis was performed using Prism 4.0 (GraphPad 
Software Inc). 
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Results 
Contractile protein composition 
MHC isoform composition was analysed by one-dimensional SDS-PAGE (Figure 3.1A, B). 
Densitometric analysis of the gels revealed that atrial tissue of patients in the sinus rhythm 
group (SR) consisted of a mixture of α- and β-MHC and that in the atrial fibrillation group 
(AF) a shift towards more β-MHC occurred (Table 3.2, Figure 3.1B). The mean values of 
β-MHC isoform content were significantly different between the SR and AF groups, but the 
ranges of MHC isoform distribution were rather similar (from 6.9 to 51.3% of total MHC 
content in SR and from 12.3 to 62.0% in AF). Ventricular samples predominantly contained 
the β-MHC isoform: only in two donor and one failing heart sample was the α-MHC 
isoform detected. 
 
Isometric force and ATPase activity 
Maximal isometric tension (i.e. force divided by cross-sectional area) did not significantly 
differ, neither between SR and AF (13.9±1.0 versus 11.0±1.5 kN/m2) nor between donor 
and failing (18.6±2.3 versus 14.6±4.3 kN/m2) myocardium. Also no difference was found 
in maximal ATPase activity between healthy and diseased myocardium both in atrial and 
ventricular tissue (Table 3.2, Figure 3.2A, B). However, on average maximal ATP 
consumption was significantly higher in atrial than in ventricular tissue. 
The average force-pCa and ATPase activity-pCa relationships obtained in atrial 
and ventricular preparations are shown in Figure 3.3. It can be noted that in atrial tissue 
Ca2+-responsiveness of force was not significantly different between SR and AF groups, 
whereas Ca2+-responsiveness of ATP consumption was significantly higher in AF 
compared to SR tissue (Table 3.2; Figure 3.3A). In ventricular tissue Ca2+-sensitivity of 
both force and ATPase activity was increased in failing hearts compared to donor 
myocardium (Table 3.2, Figure 3.3B; P<0.05). The steepness of the force-pCa and ATP-
pCa curves, nH, did not differ significantly between SR and AF atrial and donor and failing 
ventricular myocardium (Table 3.2). 
Tension cost, a measure of muscle economy, which gives information about the 
rate of ATP splitting necessary for maintenance of isometric force, was calculated by 
dividing the ATPase activity per volume by force per cross-sectional area. The mean 
tension cost was significantly different between atrial and ventricular cardiac tissue, but did 
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not differ significantly neither between SR and AF atrial nor between donor and failing 
ventricular myocardium (Table 3.2, Figure 3.2C). 
 
 
 
Figure 3.1. MHC isoform 
composition. A. Detail of the myosin 
heavy chain area of SDS-
polyacrylamide gels from atrial tissue 
of a patient in sinus rhythm (SR) and a 
patient with chronic atrial fibrillation 
(AF) and from ventricular tissue of a 
donor heart (D) and an end-stage 
failing heart (HF). B. Mean values of 
β-MHC content in the different 
groups, determined by laser 
densitometry. 
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Table 3.2. Mean parameters in atrial and ventricular tissue 
Atrial Ventricular 
Parameter 
SR (n=15) AF (n=12) D (n=6) HF (n=6) 
β-myosin heavy chain content 
(% of total MHC) 
24.6±3.2 38.1±5.7* 94.7±5.2 99.8±0.17 
Ca2+-activated ATPase activity 
per preparation volume  
(mmol⋅l-1⋅s-1) 
0.15±0.01 0.13±0.02 0.05±0.01 0.05±0.02 
Basal ATPase activity at pCa 9 
(% of total) 
10.9±0.8 13.9±1.4 11.4±1.4 14.3±2.1 
Maximal tension (kN·m-2) 13.9±1.0 11.0±1.5 18.6±2.3 14.6±4.3 
pCa50 force 5.66±0.02 5.72±0.04 5.67±0.04 5.86±0.02# 
nH force 3.09±0.19 2.81±0.17 2.29±0.29 2.75±0.26 
pCa50 ATPase activity 5.69±0.03 5.80±0.04* 5.68±0.04 5.90±0.03# 
nH ATPase activity 2.52±0.11 2.55±0.25 2.36±0.35 2.26±0.29 
Tension cost  
(mmol·kN-1⋅m-1⋅s-1) 
11.4±1.3 12.0±1.4 2.4±0.3 3.7±0.9 
Myofibrillar tissue (%) 55±6 44±7 89±2 75±9 
Interstitial space (%) 20±4 44±7* 11±2 19±2 
Maximal tension corrected for 
myofibrillar tissue (kN·m-2) 
28.4±6.3 30.7±3.7 21.1±2.1 32.5±5.6 
Ca2+-activated ATPase activity 
per preparation volume 
corrected for myofibrillar tissue 
(mmol⋅l-1⋅s-1) 
0.23±0.03 0.34±0.04 0.05±0.01 0.12±0.05 
 
Abbreviations: pCa = -log [Ca2+]. pCa50, Ca2+ concentration at which half of the maximal isometric force or ATPase activity is 
obtained; nH, steepness of pCa-force and pCa-ATPase activity relationships. Values are given as mean ± S.E.M. of n patients. 
Myofibrillar tissue and interstitial space were determined for 9 and 15 preparations of SR and AF tissue, and 5 and 3 muscle strips 
of D and HF tissue, respectively. *significant at P<0.05, atrial SR versus AF; # ventricular D versus HF. 
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Figure 3.2. Maximum isometric 
force, ATPase activity and tension 
cost. Maximum isometric force per 
cross-sectional area (A), ATPase 
activity per preparation volume (B) 
and tension cost (C) in atrial (SR, AF) 
and ventricular (D, HF) tissue. The 
differences in ATPase activity and 
tension cost were statistically 
significant (ANOVA; P<0.05) 
between atrial and ventricular tissue 
(*). No statistically significant 
differences were found in maximal 
tension between atrial and ventricular 
tissue, nor in any of the parameters 
within groups, in SR vs. AF or D vs. 
HF. 
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Figure 3.3. Ca2+-sensitivity of isometric force and ATPase activity: atrial (A), ventricular (B) tissue. 
Isometric force and the rate of ATP utilisation at submaximally activating Ca2+ concentrations are 
normalized to the control values found at saturating Ca2+ concentration (pCa 4.5). Mean values± S.E.M. are 
shown. The Hill curves defined in Materials and Methods were fitted to the mean data using their S.E.M.-s 
as a weight factor. 
 
 
Morphological structure of preparations 
Histochemical analysis was performed on 24 atrial preparations (9 SR, 15 AF trabeculae) 
and 8 ventricular (5 donor, 3 failing muscle strips) after determination of force and ATPase 
activity. It was found that the average amount of myofibrillar tissue was not significantly 
different between SR and AF atrial (55±6 versus 44±7%) and donor and failing ventricular 
preparations (89±2 versus 75±9%, Table 3.2). However, the percentage of interstitial space 
in SR preparations (20±4%) was significantly lower than in AF (44±7%). The interstitial 
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space in ventricular strips from donors was also lower than in failing strips, but this 
difference did not reach statistical significance (P=0.06; Table 3.2). 
The variable amount of myofibrillar tissue within atrial and ventricular 
preparations may alter force characteristics and energy consumption. To investigate this 
point, maximal tension and ATP consumption were corrected for the proportion of 
myofibrillar tissue. This did not result in a difference in maximal tension, but enlarged the 
difference in ATPase activity between atrial and ventricular tissue (Table 3.2). 
 
Correlation between functional properties and MHC composition 
A significant negative correlation was found between the rate of ATP consumption and 
tension cost of atrial and ventricular preparations and their MHC composition (Figure 3.4A, 
B) (r2=0.50 and r2=0.53 respectively, P<0.05). Maximal tension did not depend on MHC 
composition (figure not shown). 
After correction for myofibril density, the correlation between ATPase activity and 
β-MHC composition in a subset of the preparations used for histochemical analysis (n=32) 
slightly improved, as was reflected by an increase in the r2 value from 0.28 for the 
uncorrected data to 0.30 for the corrected data (Figure 3.4C). 
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Figure 3.4. Relation between β-MHC expression and ATPase activity or tension cost. A. ATPase activity averaged per patient. 
A significant negative correlation was found between β-MHC fraction (% of total MHC) and mean ATPase activity (SR n=14, AF 
n=11, D n=6, HF n=6). Regression line: ATPase activity/volume (in mmol⋅l-1⋅s-1) = (0.19±0.02) – (0.0015±0.0003)× β-MHC (in 
%) (r2=0.50, P<0.05). B. Tension cost averaged per patient. A significant negative correlation was found between β-MHC fraction 
(% of total MHC) and mean tension cost (SR n=14, AF n=11, D n=6, HF n=6). Regression line: tension cost (in mmol⋅kN-1⋅m-1⋅s-1) 
= (15.4±1.2) – (0.12±0.02)× β-MHC (in %) (r2=0.53, P<0.05). C. ATPase activity averaged per total preparation volume and per 
myofibrillar volume. Significant negative correlations were found between β-MHC (%) and mean ATPase activity (SR n=9, AF 
n=15, D n=5, HF n=3). Regression lines: ATPase activity/total volume (in mmol⋅l-1⋅s-1) = (0.17±0.02) – (0.0011±0.0003)× β-MHC 
(in %) (r2=0.28, P<0.05); ATPase activity/myofibrillar volume (in mmol⋅l-1⋅s-1) = (0.36±0.04) – (0.0023±0.0006)× β-MHC (in %) 
(r2=0.30, P<0.05). Meaning of symbols: open circles, SR; filled circles, AF; open squares, donor; filled squares, HF; open 
triangles: SR after correction for non-myofibrillar volume; filled triangles: AF after correction; open diamonds: donor after 
correction; open triangles: HF after correction. 
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Discussion 
Summary of the findings 
In atrial tissue a significant shift from the α- to the β-MHC isoform was observed in atrial 
fibrillation, whereas in ventricular failing myocardium no systematic changes were found 
as compared to donor tissue. Overall a significant and strong negative correlation was 
found between β-MHC content and ATPase activity. This is consistent with the notion that 
the MHC isoform shift in diseased states has a considerable impact on muscle energetics. 
However, the functional properties of the myosin heavy chain isoforms were not affected in 
health and disease. 
 
Structural and functional differences in healthy atrial and ventricular human myocardium 
To assess the mechanical and energetic properties of atrial and ventricular tissue, both their 
contractile protein composition and myofibrillar density need to be taken into account. In 
healthy human atrial tissue an approximately equal distribution is found between the fast 
and slow MHC isoform, whereas in the ventricles the slow MHC isoform predominates. 
Our data obtained in permeabilised preparations enable us to assess the implications of 
structural differences in myofibrillar density on force production and the rate of ATP 
utilisation. These parameters are equally influenced by myofibrillar density. Hence tension 
cost, a measure of economy, does not dependent on density. However, to extrapolate the 
findings to cardiac performance in vivo, effects arising from permeabilisation (i.e. washout 
of mitochondria and possibly myofibrillar swelling102,103) and alterations in geometry of the 
heart during disease need to be taken into account. 
After correction for non-myofibrillar space, force in atrial tissue was 1.3-fold 
larger than in ventricular tissue. In addition, the economy of force maintenance in atrial 
tissue was approximately 5-fold larger than in ventricular tissue. In these respects, atrial 
tissue resembles fast and ventricular tissue resembles slow skeletal muscle. In terms of 
crossbridge kinetics, it can be concluded that the rate of crossbridge formation (f) and of 
crossbridge dissociation (g) co-vary roughly in proportion, but that in atrial tissue f is 
increased more that g as compared to ventricular tissue. Since atrial tissue contains more α- 
than β-MHC, this also applies to the kinetics of the pure MHC isoforms. 
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MHC shift in atrial fibrillation 
Atrial fibrillation is the most prevalent sustained arrhythmia affecting 2.2 million adults 
only in the United States every year.104 Although contractile remodelling of atria in atrial 
fibrillation has been described already long time ago,105 the molecular mechanisms 
underlying contractile alterations are still poorly resolved. 
In our study we have also found, on average, a 13.5% increase in β-MHC content 
in AF cardiac tissue. It should also be noted that β-MHC isoform content in AF tissue 
varied considerably (range from 12.3 to 62.0%), which can explain why no significant 
differences were observed in the mean values for ATPase activity and tension cost between 
SR and AF groups. 
It is known that rat cardiac myocytes with predominant β-MHC develop lower 
power output and velocity of contraction than those with mostly α-MHC.70 The influence 
of MHC alterations in fibrillating atria is, presumably, rather small, since the atrial 
contribution under these conditions is minor. However, the impact of an isoform shift will 
become apparent upon cardioversion. Then a shift to β-MHC may be detrimental since it 
may contribute to blood stasis and consequently promote clot formation, embolism and 
stroke in AF patients.106  
Ca2+-sensitivity of ATP consumption was significantly higher in AF than in SR 
patients, while Ca2+-sensitivity of force did not differ. This implies that tension cost in AF 
patients decreases with an increase in Ca2+ concentration. There are two possible 
explanations for this observation. The first possibility would be the presence of an 
additional ATPase in AF, with a lower EC50 than the actomyosin ATPase, which is not or 
incompletely eliminated by the Triton treatment. The second possibility would be that in 
AF patients the actomyosin ATPase is more sensitive to Ca2+ than the force development. 
All methodological factors, which artefactually could give rise to a discrepancy between the 
Ca2+-sensitivity of ATPase and force (ADP and/or inorganic phosphate accumulation, 
internal shortening) have the opposite effect. It should be noted that an increased Ca2+-
sensitivity of ATPase activity would be detrimental, since more ATP would be required to 
maintain force. 
Noteworthy is the observation that atrial tissue from AF patients had a 
significantly higher amount of interstitial space if compared to patients in SR. However, 
one should be careful relating this solely to atrial fibrillation. It was shown that valve 
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disease itself could cause fibrosis.107 Since the AF group consisted mostly of patients 
suffering from valve insufficiency in contrast to the SR group with mostly coronary bypass 
patients, both factors (valve disease and AF) can be responsible for the observed fibrosis. 
 
MHC isoform shift in ventricular failing hearts 
In human ventricles the β-MHC isoform is predominant and amounts to 90-99% of total 
MHC composition. Thus, only a minor shift toward more β-MHC in failing ventricles is 
possible.34 Based on the steep relation between ATP consumption and MHC composition 
even a small shift in MHC composition could alter myocardial pump function and 
energetics.79 However, in the present study no differences were found in MHC composition 
and functional properties at maximal activation between healthy and failing human 
ventricular tissue indicating that an MHC shift is not a prominent feature under pathological 
conditions in ventricles as it is in the atria. 
In ventricular failing myocardium both force and ATP utilization were more 
sensitive to Ca2+ than in donor ventricular tissue. A similar observation was made in single 
cardiomyocytes isolated from donor and failing human hearts.39,40 The increased 
myofilament Ca2+-responsiveness in failing ventricular myocardium results most likely 
from post-translational modification of proteins. Adrenergic stimulation of the heart results 
in phosphorylation of troponin I and a reduction in Ca2+-sensitivity. In human heart failure, 
overstimulation of the β-adrenergic receptors leads to desensitisation of the β-adrenergic 
pathway. As a result troponin I phosphorylation is decreased in human failing ventricular 
tissue, which may explain the increased Ca2+-responsiveness.40 
 
MHC isoform shift in diseased myocardium, adaptive or maladaptive? 
The question, which remains to be answered, is whether the changes in MHC composition 
are beneficial for patients or on the contrary, aggravate the disease. Based on the correlation 
found in our study we can conclude that the mean shift toward β-MHC observed in AF 
would result in a decrease in ATP utilisation by 13%. As has been noted previously79 it 
seems beneficial that ventricles, which deliver most of the cardiac work, contain 
predominantly β-MHC isoform, which is slow, but more economical, i.e. require less 
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energy during isovolumic contractions. Similarly, the increase in β-MHC content in atria 
has a compensatory effect on heart function (schematically illustrated in Figure 3.5). 
             
Figure 3.5. Changes in MHC composition in atria and ventricles during disease. In healthy 
myocardium the contribution of the atria to the ventricular filling is relatively small (around 20%). In 
diseased myocardium the role of the atrial contraction to the myocardial pump function increases and a shift 
in MHC isoform composition occurs in both atria and ventricles. 
 
At rest the atria, which contain a mixture of both MHC isoforms, play a relatively 
small role in ventricular filling and cardiac pump function, but their contribution to 
ventricular filling increases under stressful conditions or during physical exercise, where 
the speed of contraction becomes more important. Similarly, during heart failure (but not 
atrial fibrillation) the relative contribution of atria to cardiac pump function increases. 
Under critical pathological conditions saving of energy in order to preserve cardiac function 
at rest will be more important than maintaining heart function during exercise and 
cardiovascular stress. 
In a recent in vivo study in transgenic mice with almost complete replacement of 
the normally predominant α-MHC isoform with β-MHC85 cardiac contractile function was 
reduced. However, animals were healthy, had a normal life span, and had no cardiac 
pathology suggesting that such an MHC isoform shift does not induce disease on its own, 
but appears to be disadvantageous only under severe cardiovascular stress. 
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Conclusion 
The shift towards the slow and more energetic β-MHC isoform occurs both in human 
diseased atrial and ventricular myocardium, but this shift is considerably smaller in 
ventricles than in atria. The shift in MHC composition towards the β-MHC isoform in atrial 
tissue may be beneficial under pathological conditions, despite a reduction in speed of 
contraction, since less energy is required to maintain pump function at rest. 
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Abstract 
The specific and selective proteolysis of cardiac troponin I (cTnI) has been proposed to 
play a key role in human ischemic myocardial disease, including stunning. In this study the 
functional implications of cTnI proteolysis were investigated in human cardiac tissue. The 
predominant human cTnI degradation product (cTnI
1-192) and full length cTnI were 
expressed in E. coli, purified, reconstituted with the other cardiac troponin subunits and 
subsequently exchanged into human cardiac myofibrils and permeabilised cardiomyocytes, 
isolated from healthy donor hearts. Maximal isometric force and kinetic parameters were 
measured in myofibrils, using rapid solution switching. To determine the effect of cTnI
1-192 
on Ca2+-responsiveness of the contractile apparatus, force development was measured at 
various calcium concentrations in single cardiomyocytes. Protein analysis by 1D-SDS gel 
electrophoresis, Western Immunoblotting and 3D-imaging revealed that approximately 
50% of endogenous cTnI was homogeneously replaced by cTnI
1-192 in both myofibrils and 
cardiomyocytes. Maximal tension was not affected, while the rates of force activation and 
redevelopment as well as relaxation kinetics were slowed down. Ca2+-sensitivity of the 
contractile apparatus was increased in preparations containing cTnI
1-192 complex (pCa50: 
5.73±0.03 versus 5.52±0.03 for cTnI
1-192 and full-length cTnI exchanged cardiomyocytes, 
respectively). These results indicate that degradation of cTnI in human myocardium will 
mainly impair diastolic function. 
 
 
Introduction 
Myocardial ischemic disease is manifested in a mild form of reversible contractile 
dysfunction (stunning) and a devastating, irreversible form (necrosis). The latter may only 
be prevented by timely restoration of coronary perfusion but even then, reversible 
contractile dysfunction is frequently apparent. The specific and selective proteolysis of 
cardiac troponin I (cTnI) has been proposed to play a key role in human myocardial 
ischemia/reperfusion injury, including stunning.38,45,46 cTnI is part of the cardiac troponin 
(cTn) complex, that in concert with tropomyosin (TM), regulates muscle contraction in 
response to a rise in intracellular Ca2+. The troponin complex consists of 3 subunits: 
troponin C (cTnC), the Ca2+ binding protein; cTnI, which inhibits the actin-myosin 
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interaction and troponin T (cTnT), which transduces the Ca2+ binding signal to TM.19 A 
recent study on crystal structures of human cTn by Takeda et al.25 indicated that upon Ca2+ 
binding to the regulatory site of cTnC, the C-terminal portion of cTnI moves away from the 
actin filament, thereby altering the orientation and/or flexibility of cTn and TM relative to 
the actin filament. Hence, cTnI plays a pivotal role in transducing the Ca2+-binding signal to 
activation of cardiac myofilaments and truncation of the cTnI C-terminus, as observed in 
human ischemic cardiac disease, might alter the Ca2+ induced force development of the 
myofilaments as well as the inhibition of force development at low Ca2+ concentrations. 
In rodents, McDonough et al.108 showed that with moderate ischemia/reperfusion 
cTnI is cleaved at its C-terminus resulting in a degraded subunit cTnI1-193. Ischemia-
induced cTnI degradation has been attributed to activation of the Ca2+-dependent proteolytic 
enzyme calpain-1 by the Ca2+ overload during reperfusion.109 Increased preload in the absence 
of ischemia has also been shown to initiate cTnI degradation.110 In a post-infarct pig model, 
minor degradation of cTnI (<4%) was observed in the viable remodelled left ventricle.111 
The maximal force generating capacity of the myofilaments in these experiments was 
reduced compared to myocardium of sham-operated animals. In advanced human heart 
failure serum cTnI elevations have been reported.112 In addition, cTnI degradation has been 
found in human cardiac tissue from coronary artery disease patients with different degrees 
of heart failure and a history of myocardial infarction. 38,45,46 The primary cTnI degradation 
product found in these hearts was identified as cTnI1-192 (similar to cTnI1-193 in rodent 
myocardium108,109,113). Hence, in humans C-terminal truncation of cTnI may also underlie 
impaired cardiac function in ischemia-induced cardiomyopathy. However, the direct effects 
of cTnI proteolysis on contractile function of human cardiac myofilaments have not been 
investigated in detail. 
In this study protein engineering was combined with functional measurements to 
assess the direct effects of degradation of the cTnI C-terminus in human myocardium. 
Force measurements were performed in human cardiac myofibrils and cardiomyocytes, in 
which endogenous troponin complexes were partly replaced by complexes containing either 
human full-length cTnI or truncated cTnI1-192. The advantage of this technique is that it 
allows to investigate the direct effect of cTnI degradation on contractility of human cardiac 
preparations without degradation of other contractile proteins (as e.g. follows calpain-1 
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treatment48,114) or other compensatory protein changes, which may develop in transgenic 
animals. 
Force development at maximal and submaximal [Ca2+] and kinetic parameters of 
force activation and relaxation in preparations containing cTnI1-192 were compared to those 
containing full-length cTnI. Surprisingly, in the presence of cTnI1-192 maximal isometric 
force was preserved, Ca2+-sensitivity was increased and the kinetics of activation and 
relaxation of human cardiac preparations were slowed. These data were unexpected since 
previous studies showed a loss in maximum force and an acceleration of the actomyosin 
ATPase kinetics.113,115,116 Our data indicate that C-terminal truncation of cTnI mainly 
impairs diastolic properties of human myocardium. 
 
 
Materials and Methods 
Preparation of recombinant troponin complex 
The human cardiac full-length cTnI and truncated cTnI (cTnI1-192) peptides were prepared 
using the standard F-moc synthesis. All human troponin subunits (human cTnI and cTnI1-
192, cTnT and cTnC) were expressed separately in E. coli and purified using ion-exchange 
chromatography. The purified troponin subunits were reconstituted into a full troponin 
complex by mixing the subunits in a 1:1:1 molar ratio. After 2 hours incubation at room 
temperature the concentration of urea (6M) and KCl (1M) were reduced by step-wise 
dialysis117. Purity and stoichiometry of both reconstituted complexes, containing either full-
length cTnI (cTnFL) or the primary cTnI degradation product (cTnDEG), was verified by one-
dimensional gel electrophoresis (described below). Protein complexes were stored at -80◦C 
prior to the experiments. 
 
Isolation of human myofibrils and cardiomyocytes 
Left ventricular tissue was obtained from healthy donor hearts (n=2), frozen in liquid 
nitrogen and stored at -80◦C. Samples were obtained after informed consent and with 
approval of the local ethical committees. The investigation conformed with the principles 
outlined in the Declaration of Helsinki.118 
Single myofibrils or bundles of two to three myofibrils were prepared from these 
biopsies, as described previously.119 Shortly, small pieces of frozen ventricular tissue (70-
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100 mg) were defrosted in rigor solution (10 mM Tris, 132 mM NaCl, 5 mM KCl, 1 mM 
MgCl2, 5 mM EGTA, 2 mM DTT, 10 mM NaN3, pH 7.1), dissected in a few thin muscle 
strips (diameter 0.5-1.0 mm) and permeabilised in rigor solution containing 1% Triton X-
100 for 2 hours on ice. To remove Triton, myofibrils were washed in rigor solution 3 times. 
Thereafter muscle strips were homogenized with a blender for 10 s at 4 ºC to produce a 
suspension of human cardiac myofibrils. Exchange of troponin complexes was started 
immediately after myofibril isolation. All solutions to which the myofibrils were exposed 
contained a protease inhibitor cocktail (0.2 mM PMSF, 0.01 mM leupeptin, 0.01 mM E-64 
and 0.005 mM pepstatin, Sigma). 
Single cardiac myocytes were mechanically isolated using the protocol described 
previously60 except that the tissue was handled in cold rigor solution rather than in relaxing 
solution. The cells were permeabilised in rigor solution supplemented with 0.5% Triton X-
100 for 5 min on ice, subsequently washed and used for exchange. 
 
Exchange of human cardiac cTn complex 
Exchange of human cardiac troponin complex into human myofibrils and myocytes was 
performed according the method of Brenner et al.120 Myofibrils and cardiomyocytes were 
incubated overnight at 4 °C in an exchange solution containing 0.5 mg/ml (ca 6 μM) of 
human troponin complex (either cTnFL or cTnDEG). Composition of the exchange solution 
was in mM: imidazole 10, NaCl 170, MgCl2 5, CaCl2 3, EGTA 2.5, DTT 0.5, NaN3 0.5, pH 
6.9 and the protease inhibitor cocktail described above. After exchange the myofibril and 
cardiomyocyte suspensions were washed twice by centrifugation (at 4000g for 10 min at 
10°C and 900g for 1 min at 4°C, for myofibrils and cardiomyocytes, respectively) to 
replace the exchange solution with rigor solution. Half of the suspension was used for 
mechanical experiments, and the remaining half was used for analysis of the amount of cTn 
exchange by one-dimensional gel electrophoresis. 
 
Force measurements in exchanged human myofibrils and cardiomyocytes 
The set-up used for rapid solution changes and to record force in single myofibrils was as 
described previously.28,121 Briefly, myofibrils were mounted horizontally between a 
calibrated cantilever force probe and a motor. Sarcomere length and myofibril diameter 
were measured from video images (magnification 1800X, phase-contrast optics). The initial 
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length of attached myofibrils between the attachments (mean ± S.E.M.), respectively, 
amounted to 2.20±0.04 μm (n=17) in the cTnFL exchanged myofibrils and to 2.19±0.04 μm 
(n=25) in cTnDEG exchanged myofibrils. 
Myofibrils were activated and relaxed by rapid (10 ms) switching between two 
continuous streams of relaxing (pCa 9; pCa = -log10[Ca2+]) and activating (pCa 3.5) 
solutions flowing by gravity from a double-barrelled glass pipette placed at right angles to, 
and within 1 mm of, the preparation. A release–restretch protocol was used to measure the 
rate of force redevelopment (KTR).28 The rate of rise of force following the step decrease in 
pCa by fast solution switching (KACT) was estimated from the time required to reach 50% 
of the maximum isometric force. 
Isometric force in single human cardiomyocytes was measured at different [Ca2+] 
(pCa ranging from 4.5 to 6.0) and at a sarcomere length of 2.2 μm as described 
previously.60 Maximal activation at pCa 4.5 was used to calculate maximal calcium-
activated isometric tension (i.e. Fmax/cross-sectional area). The cross-sectional area of the 
preparations was calculated assuming an elliptical shape, i.e. cross-sectional area = (width × 
depth × π) / 4. Accurate determination of myocyte depth was done by projecting the 
myocyte via a small mirror onto the objective of the inverted microscope.122 Mean 
dimensions (± S.E.M.) of the cTnFL (n=14) and cTnDEG (n=14) exchanged cardiomyocytes 
amounted to 48.5±2.6 and 58.3±5.1 μm in length, 18.2±1.6 and 16.7±1.5 μm in width, and 
19.7±2.1 and 17.0±1.6 μm in depth, respectively. After maximal activation 4 to 5 
measurements were carried out at submaximal [Ca2+] (pCa>4.5) followed by a maximal 
activation. Force values obtained in solutions with submaximal [Ca2+] were normalized to 
the interpolated maximal force values (pCa 4.5). On average force decline between the first 
and the last maximal control activation amounted to 10±3% and 14±1% for cTnFL and 
cTnDEG exchanged cardiomyocytes, respectively. Experiments where force decline 
exceeded 25% were discarded. Passive force was determined as indicated in Figure 4.5. All 
mechanical experiments were performed at 15°C. 
 
Protein analysis 
The amount of cTnI exchange was analysed in cardiac samples in which endogenous cTnI 
was replaced by cTnI1-192. It has been shown previously for rabbit psoas myofibrils that the 
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amount of human full length cTnI exchange was the same as for cTnI1-192.123 Hence, in the 
present study evaluation of both cTnFL and cTnDEG exchange into human cardiac 
preparations was based on the amount of cTnI1-192 exchange. This analysis was performed 
using Coomassie stained one-dimensional SDS-polyacrylamide gel electrophoresis (1D 
SDS-PAGE) and was based on the reduction in the ratio between endogenous cTnI and α-
actinin in cTnDEG preparations compared to cardiac samples, which were incubated in 
exchange solution without exogenous cTnI. The α-actinin band was chosen as a measure of 
myofibrillar protein loading because its intensity was within the linear range and not 
affected by the exchange procedure. 
The separating gel of 1D SDS-PAGE used for the extent of cTnDEG exchange 
determination contained 15% total acrylamide (acrylamide to bis-acrylamide ratio 200:1; 
pH 9.3), while the stacking gel contained 3.5% total acrylamide (acrylamide to bis-
acrylamide ratio 20:1; pH 6.8). Cardiomyocytes and myofibrils were dissolved in standard 
Laemmli sample buffer.124 Gels were stained with 0.1% Coomassie solution and analysed 
by laser densitometry (LKB Produkter AB, Bromma, Sweden) using the GelScan XL 
software package (Pharmacia, Uppsala, Sweden). To check for linearity, different amounts 
of tissue were loaded and the intensity of the cTnI and α-actinin bands was analysed. 
Protein content of the cardiomyocyte suspension was determined using the RC-DC protein 
concentration assay kit (BioRad). Based on these determinations protein loads <90 μg were 
found to be within the linear range. 
The cTnI, cTnI1-192 and α-actinin bands on gel were identified and the amount of 
troponin complex exchange was confirmed by Western immunoblotting. Semi-dry blotting 
was performed at 45 Volt for 90 min, using the discontinue system.125 Staining with the 
specific antibodies directed against troponin I (8I-7, Research Diagnostics Inc, dilution 1:10 
000) and α-actinin (clone EA53, Sigma, dilution 1:200) was done using the Vectastain 
ABC-Amp protocol (Vector laboratories, Burlingame, USA). 
 
Microscopy 
To check if the cTn complex was homogeneously incorporated into cardiomyocytes, 
cTnDEG exchanged cardiomyocytes were studied using a Marianas™ digital imaging 
microscopy workstation equipped with a nanostepper motor (Z-axis increments: 10 nm) and 
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a cooled CCD camera (Cooke Sensicam, Cooke Co, Tonawanda, NY, USA). The 
microscope, and camera were controlled by SlideBookTM software (SlideBook 4.1.0.9, 
Intelligent Imaging Innovations, Denver, CO, USA). After the exchange protocol 
cardiomyocytes were fixed with 4% paraformaldehyde. The cTnI1-192 exchange into 
cardiomyocytes was examined using a specific antibody directed against amino acid 
residues 195-209 in the C-terminus region of cTnI (clone P45-3, Research Diagnostics Inc, 
dilution 1:50) and a secondary fluorescent antibody Alexa Fluor 488 (Molecular Probes, 
dilution 1:40). Images were acquired in the Z-axis direction with a step size of 0.5 μm. 
Image processing and data analysis was performed using SlideBookTM and ImageJ (public 
domain software available at http://rsb.info.nih.gov/ij/). Images were deconvoluted using 
the constrained interactive mode, with interpolation of 1 plane between each acquired plane 
and mirror edge padding at the Z-axis (20 planes). 
 
Data analysis 
Force-pCa relations were fit to a Hill equation:67 
 F(Ca2+)/F0=[Ca2+]nH/(Ca50nH +[Ca2+]nH), 
where F is steady state force. F0 denotes the steady force at saturating Ca2+ concentration, 
nH reflects the steepness of the relation, and Ca50 (or pCa50) represents the midpoint of the 
relation. 
Values are given as means ± S.E.M. of n myofibrils of myocytes. Differences were 
tested by means of unpaired two tailed Student’s t-tests at a level of significance of 0.05. 
 
 
Results 
Amount and distribution of exchanged troponin complex in human cardiac preparations 
The amount of exchange was analysed in cTnDEG exchanged cardiac samples based on the 
decline in the ratio between endogenous cTnI and α-actinin using Coomassie stained 1D 
SDS-PAGE. Figure 4.1A shows an example of a gel of exchanged cardiac myofibrils. 
Replacement of the endogenous troponin complex with cTnDEG amounted to 54±6% (n=4) 
in human cardiac myofibrils and to 50±2% (n=5) in human cardiomyocytes. These data 
were confirmed by Western blots using a specific antibody against cTnI, shown in Figure 
4.1B for myofibrils and in Figure 4.1C for cardiomyocytes. 
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Figure 4.1. A. SDS polyacrylamide gel of suspensions of human myofibrils after the exchange procedure with full length cTnI 
(cTnFL), degraded cTnI (cTnDEG) or without exogenous cTn complex (control condition, CTR). Evaluation of the exchange was 
performed using the density ratio between endogenous cardiac TnI (cTnI) and α-actinin, as a reference of the amount of protein 
load. B. Subsequent Western immunoblot of a SDS-PAGE gel from human myofibrils using an antibody recognizing the full-
length (cTnI) as well as the truncated form (cTnI1-192). C. Western immunoblot of cTnI in exchanged human cardiomyocytes. D. 
Image obtained by summation of plane intensities along the Z-axis of a single cardiomyocyte exchanged with cTnDEG, incubated 
with an antibody directed against C-terminus of cTnI. Scale bar: 10 µm. E. Distribution of the fluorescence intensity within the 
cardiomyocyte. Planes were acquired along the Z-axis (in depth) from the top of the myocyte (plane 1) to its bottom (plane 31). F. 
Distribution of the fluorescence intensity along the vertical (y-)axis of cardiomyocyte in its central part (planes 11-21). 
Abbreviations: cTnFL and cTnDEG denote troponin complex with full-length cTnI and truncated cTnI (cTnI1-192), respectively; 
myofibrils cTnFL and cTnDEG denote myofibrils exchanged with cTnFL and cTnDEG, respectively; CTR denotes myofibrils treated 
similarly, but without cTnI complexes; MW: molecular weight marker. 
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To test if the cTn distribution in cardiomyocytes is homogeneous after the exchange, 
human cardiomyocytes exchanged with cTnDEG were stained with a specific antibody P45-3 
and studied using 3D digital imaging microscopy. P45-3 can react only with full-length 
cTnI and not with truncated cTnI1-192, thus staining with this antibody may reveal 
inhomogeneity of cTnDEG exchange into the cardiomyocytes. A summation in the Z-axis of 
the X-Y images of a representative cardiomyocyte is shown in Figure 4.1D. Fluorescence 
intensity was averaged per plane and plotted against plane number in Figure 4.1E. This 
panel illustrates that with overnight incubation the penetration of cTn into the 
cardiomyocyte is not limited by diffusion. The fluorescence intensity distribution in the Y-
axis direction (Figure 4.1F) in the central part of the myocyte also reveals a rather 
homogeneous distribution of cTn complex within the exchanged cardiomyocyte. 3D image 
reconstruction performed in 3 typical cTnDEG exchanged cardiomyocytes showed similar 
results. This indicates that the protocol used ensures a uniform exchange of cTnDEG inside 
the cardiomyocytes (and in the much thinner myofibrils). 
 
Force measurements in exchanged human myofibrils 
Original recordings of force production in myofibrils at saturating [Ca2+] are shown in 
Figure 4.2. Maximal isometric force (i.e. force at pCa 3.5 divided by cross-sectional area) 
was not significantly different between cTnFL and cTnDEG
 
exchanged myofibrils (Figure 
4.3A). However, the rate of force rise (KACT) and the rate of force redevelopment (KTR) 
were both significantly decreased in cTnDEG exchanged myofibrils compared to cTnFL 
exchanged myofibrils by 24 and 31%, respectively (P<0.05) (Figure 4.3B). 
After a rapid switch from activating (pCa 3.5) to relaxing (pCa 9) solution, 
isometric force started to decline (Figure 4.2). Force relaxation takes place in 2 phases: a 
slow initial linear phase, with a rate constant KREL,S calculated from its slope, and with a 
duration tSLOW, and a rapid exponential phase characterized by the rate constant KREL,F.126 
The duration of the slow phase tSLOW was significantly increased in cTnDEG exchanged 
myofibrils (0.30±0.02 s for cTnDEG versus 0.21±0.02 s for cTnFL, P<0.05), while KREL,S 
remained unchanged (0.21±0.02 s-1 and 0.31±0.05 s-1, for cTnDEG and cTnFL, respectively). 
The KREL,F significantly decreased in cTnDEG exchanged myofibrils (2.54±0.25 s-1 and 
3.75±0.37 s-1, for cTnDEG and cTnFL, respectively, P<0.05). An overview of averaged data is 
presented in Table 4.1. 
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Figure 4.2. A. Image of single human cardiac myofibril, B. representative traces of force activation and C. 
relaxation in cTnFL and cTnDEG exchanged human cardiac myofibrils. After the myofibril was transferred 
into activating solution (pCa 3.5) and active force developed the myofibril was shortened by the 20% of its 
length. Relaxation kinetics were obtained after myofibril was returned into relaxing solution (pCa 9). Scale 
bar: 10 µm. 
Chapter 4 
76 
 
Figure 4.3. A. Mean values of maximal isometric force, B. rate of force development, C. duration of relaxation slow phase and D. 
rate of relaxation of cTnFL or cTnDEG exchanged myofibrils. Maximal force, KACT and KTR were obtained at maximal [Ca2+] (pCa 
4.5). Duration, KREL,S, KREL,F were obtained at pCa 9. Values are given as mean ± S.E.M. of 22 cTnFL and 27 cTnDEG exchanged 
myofibrils. *Significant at p<0.05, cTnFL versus cTnDEG exchanged myofibrils. 
 
Table 4.1. Functional data of exchanged human myofibrils 
Parameter cTnFL cTnDEG 
Maximal force (kN·m-2) 54±12 52±9 
KACT (s-1) 0.80±0.07 0.61±0.05* 
Force 
activation 
KTR (s-1) 0.77±0.07 0.53±0.05* 
tSLOW (s) 0.21±0.02 0.30±0.02* 
KREL,S (s-1) 0.31±0.05 0.21±0.02 
Force 
relaxation 
KREL,F (s-1) 3.75±0.37 2.54±0.25* 
 
Abbreviations: cTnFL and cTnDEG denote myofibrils exchanged with cTnFL and cTnDEG, respectively. Maximal force, 
KACT and KTR were obtained at maximal [Ca2+] (pCa 3.5). tSLOW, KREL,S, KREL,F were obtained in relaxing solution (pCa 9). 
Values are given as mean ± S.E.M. of n myofibrils. *Significant at P<0.05, cTnDEG versus cTnFL. 
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Force measurements in exchanged human cardiomyocytes 
The maximal isometric force and its Ca2+-sensitivity could be determined more accurately 
in cTnFL and cTnDEG
 
cardiomyocytes than in myofibrils, because the cross-sectional area 
could be determined with a higher precision in cardiomyocytes than in myofibrils (Figure 
4.4). Force recordings of cTnFL and cTnDEG
 
exchanged myocytes are presented in Figure 
4.5. Maximal isometric force and mean passive force were not significantly different 
between cTnFL and cTnDEG exchanged myocytes (Figure 4.6). However, cTnDEG 
cardiomyocytes had a significantly higher Ca2+-sensitivity than cTnFL exchanged 
cardiomyocytes (pCa50: 5.73±0.03 and 5.52±0.03 for cTnDEG and cTnFL, respectively, 
P<0.05) (Figure 4.7). The cooperativity of force development (nH) tended to decrease in 
cTnDEG exchanged cardiomyocytes, but the difference between groups did not reach 
statistical significance (2.08±0.11 and 2.69±0.26 for cTnDEG and cTnFL, respectively, 
P=0.05). 
 
Figure 4.4. Images of single cardiomyocytes with 
exchanged cTnFL and cTnDEG. Scale bar: 25 µm. 
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Figure 4.6. A. Mean values of maximal isometric force and passive force of exchanged cTnFL and cTnDEG cardiomyocytes. 
Maximal (Fmax) and passive (Fpass) forces were obtained at saturating [Ca2+] (pCa 4.5) and at low [Ca2+] (pCa 9), respectively. 
Values are given as mean ± S.E.M. of 14 cardiomyocytes for each group. B. The Ca2+-sensitivity of isometric force of exchanged 
cTnFL and cTnDEG cardiomyocytes. Isometric force at submaximal activating [Ca2+] was normalized to the control force found at 
saturating [Ca2+] (pCa 4.5). The force-pCa relations are fitted to a Hill equation. Ca2+-sensitivity of cTnDEG cardiomyocytes was 
significantly higher (pCa50=5.71±0.03) than of cTnFL myocytes (pCa50=5.52±0.02) (P<0.05). Values are given as mean ± S.E.M. of 
9 cTnFL and 11 cTnDEG exchanged cardiomyocytes. 
Figure 4.5. Recordings of force production in 
cardiomyocytes with exchanged cTnFL and 
cTnDEG at pCa 4.5. The myocyte was shortened 
rapidly after force development reached a steady 
level to determine the baseline of the force 
transducer (zero level). After return of the 
myocyte into the relaxing solution (pCa 9) it was 
shortened again for 10 s to determine its passive 
force. 
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Discussion 
These experiments represent the first attempt to assess the direct effects of the cTnI 
degradation in human cardiac tissue. The results indicate that cTnI degradation at the C-
terminus (1) does not reduce maximal isometric force development nor results in an 
increase in passive force but (2) slows force development as well as relaxation and (3) 
enhances myofilament Ca2+-sensitivity. 
 
Comparison with previous studies on cTnI1-192 function 
The decrease in maximal force generating capacity of the cardiac muscle is one of the main 
features of reversible ischemia/reperfusion injury (stunning) in rodents and has been 
attributed to degradation of cTnI, primarily at its C-terminus.108,109,113 In a transgenic mouse 
line expressing 9-17% of C-terminus truncated cTnI of total endogenous cTnI,45,127 
maximal force development of intact trabeculae was about 40% depressed compared to 
non-transgenes. In view of these previous findings it is surprising that in our study the 
maximum force was not affected in myocytes with the truncated form of TnI. However, it 
has become increasingly clear that the processes involved in stunning differ in small and 
large animals.50 The reduction in force could, at least in part, also be due to degradation of 
other, ultrastructural proteins48 or to secondary ROS-related effects.51 Moreover, species 
differences may be involved as well. 
In a study using an in vitro motility assay with reconstituted actin filaments, a 24% 
decrease in force development was observed of filaments with human cTnI1-192 compared to 
filaments with full-length cTnI.128 In addition, exchange of the human cTnDEG complex into 
rabbit psoas myofibrils under the same experimental conditions as used in this study, 
revealed a 26% decrease in maximal force development in comparison with cTnFL 
preparations.123 A similar reduction of maximal force was observed by Tachampa et 
al.,129,130 where human or mice cTn complexes were exchanged in rat cardiac trabeculae. 
The main difference in these exchange experiments is that chimerical thin filaments were 
formed, whereas in our experiments human cardiac proteins were exchanged into human 
cardiac tissue. It is conceivable that, despite the high ~95% identity of human, mice, rat and 
rabbit amino acid sequence of cTn subunits, signal transduction and transmission between 
troponin subunits and other contractile proteins is isoform and species-dependent. This 
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might result in diverse functional changes upon cTnI1-192 exchange in matching or non-
matching species. 
In viable remote remodelled tissue after infarction in pigs, minor degradation of 
cTnI (<4%) was observed while the maximal force generating capacity was reduced.111 If 
our findings in humans are characteristic for the situation in large animal models, this 
would suggest that other factors than TnI degradation would be responsible for this loss in 
force. 
Interestingly, the results on kinetics and Ca2+-sensitivity observed in the present 
study are in line with those found in exchange experiments using rabbit psoas myofibrils 
and rat cardiac trabeculae.123,129,130 However, caution should be exerted with the 
interpretation of these findings within the context of stunning. For instance Gao et al.116 
have observed an increase in KTR and also provided evidence suggesting that the rate 
limiting step of the transition from force-generating to non-force-generating states was 
accelerated in stunned myocardium. Moreover, there is no consensus in the literature 
regarding the direction of the change in the maximum shortening velocity in stunned 
myocardium.131 
 
Structural and biochemical considerations on cTnI1-192 exchange 
Recently the atomic structure of human cTn in the Ca2+-saturated form has been resolved 
using x-ray crystallography.25 It was concluded that Ca2+ binding to cTnC induces 
detachment of the C-terminus region of cTnI from actin, thereby altering the mobility 
and/or flexibility of cTn and tropomyosin (TM) on the actin filament. There is good 
correspondence between this structural model27 and the three-state biochemical26 model 
where tropomyosin can exist in a blocked (B), closed (C) and an open (M) state. In the 
absence of Ca2+, troponin stabilizes TM in a state that sterically blocks actin interaction 
with myosin (blocked state). Upon Ca2+ binding to cTnC the inhibition is released, and TM 
adopts a state that allows myosin to bind weakly to actin (closed state). Upon binding of 
myosin, TM moves further, which allows more and stronger myosin binding to actin, by 
cooperative propagation along the actin filament (open state). Previous studies indicate that 
the presence of cTn and TM enhance force development and also influence kinetic 
parameters of crossbridge interaction.132-134 This suggests that TnI degradation may affect 
the maximum force generating capacity as well as the kinetics activation and relaxation of 
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force. If steric hindrance of the C-terminal end of TnI would be important, as suggested 
previously,128 its truncation would tend to increase the number of interacting crossbridges 
(i.e. force) rather than to decrease it. 
The increase in Ca2+-sensitivity can be caused by (1) an increase in Ca2+ affinity of 
cTnC, which promotes the transition from blocked to closed state and/or (2) enhancement 
of myosin binding to actin, the transition from closed to open state.20,135 It has been shown 
using various truncated forms of cTnI that progressive deletion of parts of the C-terminal 
impairs the ability of cTnI to bind to actin-tropomyosin at low [Ca2+], promoting the 
availability of actin for binding with myosin.136 This is consistent with the increase in Ca2+-
sensitivity observed in our experiments. The nH of cardiomyocytes exchanged with cTnDEG 
tended to be lower than that of cTnFL exchanged cardiomyocytes. This may reflect a 
decrease in cooperativity of thin filament activation, in agreement with the destabilization 
of TM on actin. 
KACT and KTR of the cTnDEG exchanged cardiomyocytes were both significantly 
decreased. Evidence suggests that KACT and KTR are mainly determined by the kinetics of 
the crossbridge attachment.28 The parallel changes in KACT and KTR observed is these 
experiments are most likely due to cooperative changes within the thin filament that lead to 
the transition to the open state. Thus, the decreased cooperativity of thin filament regulation 
may play a role in the slowing of the activation kinetics. 
It has been shown that during the first slow linear phase of relaxation all 
sarcomeres remain isometric, whereas the fast relaxation phase starts when the first 
mechanically weakest sarcomere ‘gives’.126,137 The slow KREL,S is determined largely by the 
isoform of myosin heavy chain.126 This may explain the lack of a significant effect of cTnI 
degradation on this parameter in our experiments. The duration of the slow phase tSLOW was 
however increased in cTnDEG exchanged preparations, i.e. sarcomeres remain isometric for a 
longer time during relaxation. This might be a consequence of the increased Ca2+-
sensitivity. Moreover, it has been shown that the fast KREL,F depends inversely on the final 
steady-state force after relaxation.138 Since cTnI1-192 incorporation into myofilaments 
increases Ca2+-sensitivity, the force during relaxation is larger and accordingly the fast 
KREL,F will be decreased. Thus, changes in both tSLOW and fast KREL,F may be linked to the 
increased Ca2+-sensitivity. 
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In a simple two-state model for crossbridge interaction the maximum isometric 
force is proportional to the number of crossbridges in the force generating state (N), i.e. 
f/(f+g) and KTR=f+g, where f equals the rate of crossbridge attachment and g equals the rate 
of cross-bridge detachment.28 If we assume that at saturating Ca2+ concentrations g=KREL,S, 
N equals 0.6, both for cTnFL and cTnDEG. Hence, the kinetic values observed are consistent 
with the preservation of the maximum force-generating capacity. 
 
Implications for the cardiac function in vivo 
The amount of cTn exchange into cardiac preparations in our experiments was 
approximately 50%, while the degree of cTnI degradation observed in failing human 
myocardium was less (up to 26%).46 When the concentration of Tn complexes during 
exchange was doubled, the amount of exchange increased to about 73%. Under these 
conditions, the decrease in the activation kinetics of cTnDEG exchanged rabbit myofibrils 
compared to cTnFL exchanged myofibrils was found to be more pronounced (unpublished 
data). Thus, we expect that the slowing of the kinetics and the increase in Ca2+-sensitivity in 
failing human myocardium will be less pronounced than observed in our study. 
The slowing of relaxation and the increase in Ca2+-sensitivity of cardiac 
preparations after cTnI1-192 exchange observed in the present study suggest that cTnI 
degradation in vivo might impair cardiac relaxation and contribute to diastolic dysfunction. 
On the other hand, the increased myofilament Ca2+-sensitivity with preserved maximal 
force generating capacity implies that at Ca2+ concentrations present during systole more 
force will be developed. However, during a twitch this effect will be counteracted by the 
slowing of force development in preparations with cTnI1-192. This will lower the peak force 
developed during systole suggesting that the net-effect may be rather small. Hence, our data 
indicate that diastolic dysfunction in human myocardium following (acute) ischemia139,140 
might, at least in part, be due to cTnI proteolysis. 
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Abstract 
The C-terminal proteolysis of cardiac troponin I (cTnI) has been proposed to play a key role 
in human ischemic myocardial disease, including stunning. Previously it has been shown 
that cTnI proteolysis has a large functional effect in human cardiac tissue. In this study the 
ability of the human myofilaments containing degraded cTnI to modulate their activity in 
response to changes in cardiac pump function and meet higher hemodynamic demands was 
investigated. The predominant human cTnI degradation product (cTnI
1-192) and full length 
cTnI were expressed in E. coli, purified, reconstituted with the other cardiac troponin 
subunits and subsequently exchanged into permeabilised human cardiomyocytes, isolated 
from healthy donor hearts. To determine the effect of cTnI
1-192 on regulation of contractile 
function, force development was measured in single cardiomyocytes at various calcium 
concentrations, at sarcomere lengths of 1.9 and 2.2 μm, and after treatment with the 
catalytic sub-unit of protein kinase A (PKA), to mimic β-adrenergic stimulation. The 
sarcomere length dependency of force development and the desensitising effect of PKA 
were preserved in cTnI
1-192 exchanged cardiomyocytes. These results indicate that 
degradation of cTnI in human myocardium does not affect β-adrenergic and preload-
dependent responses. 
 
 
Introduction 
A detrimental role of cardiac troponin I (cTnI) degradation has been implicated in human 
ischemic heart disease. 38,45,46 Degradation of cTnI was observed in viable cardiac tissue of 
patients who required surgery for ischemic disease 45,46 and transplant hearts of patients 
diagnosed with an extensive coronary artery disease. 38 Strong evidence for involvement of 
cTnI C-terminal degradation in reversible ischemia/reperfusion injury (i.e. stunning) is 
arising from animal studies.45,108,109 Recently, we have shown that exchange of cTnI1-192 
(which corresponds to the primary degradation product observed in human cardiac ischemic 
tissue) into human cardiac myofibrils and cardiomyocytes results in a substantial slowing of 
force generation and relaxation kinetics, an increase of Ca2+-sensitivity, but has no effect on 
maximal force (Chapter 4). These results indicate that cTnI proteolysis found in ischemic 
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heart disease may impair diastolic function and contribute to the development of heart 
failure in humans. 
Cardiac TnI has a central position in the signaling pathway connecting Ca2+-
binding to the troponin complex (cTn) to myosin binding to actin. Recently, structural data 
obtained by X-ray crystallography25 revealed that the N-terminus of cTnI binds to cardiac 
troponin C (cTnC) and cardiac troponin T (cTnT), while its central inhibitory region (IR) 
and C-terminal domain in the absence of Ca2+ are attached to the actin filament (Chapter 1, 
Figure 1.3). These interactions with tropomyosin (TM) and actin impede myosin binding to 
actin. When Ca2+ binds to cTnC, both the IR and C-terminal domain move away from the 
tropomyosin and actin and allow myosin binding to actin. Thus, the loss of either IR or C-
terminal domain of cTnI would be expected to alter the mechanism of Ca2+ regulation of 
muscle contraction and substantially affect the pump function of the human heart. 
Cardiac TnI is not only essential for Ca2+-regulation of cardiac myofilament 
activation, but also is important in the adjustment of myofilament activity to changes in 
hemodynamic demands. Prominent mechanisms by which cardiac myofilament activation 
process is coupled to the prevailing hemodynamic state and beating frequency include (1) 
sympathetic nervous system, through protein kinase/phosphatase pathways and 
(de)phosphorylation of regulatory proteins, and (2) ventricular filling (preload): the Frank-
Starling mechanism.141 
Regulation by sympathetic nervous system involves β-adrenergic receptor 
stimulation with subsequent phosphorylation of cTnI by protein kinase A (PKA) at its N-
terminus (Ser 23 and 24). Phosphorylation of cTnI by the catalytic subunit of PKA causes a 
decrease in Ca2+-sensitivity of isometric force production in human cardiomyocytes. 
39,142,143
 It has been shown by measurements of Ca2+-controlled thin filament– activated 
myosin S1-ATPase activity and in vitro motility assays that a mutation in the cTnI C-
terminus (K206Q), known to cause familial hypertrophic cardiomyopathy, reduces the 
effect of PKA treatment.144 This suggests that cTnI C-terminal domain composition is 
important in PKA signal transduction. 
The dependence of ventricular systolic pressure on ventricular volume (as a result 
of diastolic filling) is commonly known as the Frank-Starling law of the heart. The cellular 
basis underlying the Frank-Starling mechanism is the increase in contractile force with an 
increase in sarcomere length. This occurs due to the change in the overlap of actin and 
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myosin and an increase in Ca2+-sensitivity of force development.145,146 The molecular 
mechanisms underlying the length-dependent alteration of Ca2+-sensitivity are still obscure. 
However, it has been shown that the increase in Ca2+-sensitivity associated with the 
increase in sarcomere length was significantly blunted in cardiac myofilaments dissected 
from transgenic mice expressing slow skeletal troponin I.147 This suggests that cTnI is an 
important determinant of the length-dependent activation of cardiac myofilaments. 
The aim of this study was to elucidate whether or not the human myofilaments 
containing degraded cTnI would be able to modulate their activity in response to changes in 
cardiac pump function and meet higher hemodynamic demands. More specifically, the 
question was studied whether partial degradation of cTnI from its C-terminus has such a big 
impact on its structure that it would alter PKA-induced phosphorylation of cTnI as well as 
length-dependence of activation.16 
To address this question force measurements at maximal and submaximal [Ca2+] 
were performed in human cardiomyocytes, in which endogenous troponin complexes were 
replaced by complexes containing either human full-length cTnI or truncated cTnI1-192. The 
force measurements were performed at a sarcomere length of 1.9 and 2.2 μm and before 
and after PKA treatment. The results indicated that cTnI1-192 did not affect the length 
dependency of force activation and the effect of PKA-induced phosphorylation of human 
cardiac myocytes. 
 
 
Materials and Methods 
Preparation of recombinant troponin complex, isolation of human cardiomyocytes and 
exchange of cardiac Tn complex into cardiomyocytes were performed as described in 
Chapter 4. 
 
Force measurements in exchanged human myofibrils and cardiomyocytes 
Isometric force in single human cardiomyocytes was measured at different [Ca2+] (pCa= -
log [Ca2+] ranging from 4.5 to 6.0) and at a sarcomere length of 1.9 and 2.2 μm as described 
previously.60,142 After attachment the cardiomyocyte was stretched to a sarcomere length of 
1.9 μm. After an initial maximal activation 6 measurements were carried out at submaximal 
[Ca2+] (pCa>4.5) followed by maximal activation. Force values obtained in solutions with 
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submaximal [Ca2+] were normalized to the interpolated maximal force values (pCa 4.5). 
The decrease in maximal force during this first force-pCa series amounted to 2±1% for 
cardiomyocytes containing cTnFL and 2±3% for cardiomyocytes containing cTnDEG. 
Thereafter the cardiomyocyte was stretched to a sarcomere length of 2.2 μm, and force 
measurements at maximal and submaximal [Ca2+] were repeated. After the full force-pCa 
curve was obtained, the cardiomyocyte was incubated for 40 min at 20°C in relaxing 
solution containing 6 mmol/l dithiothreitol (DTT) and the catalytic subunit of PKA (3 mg/l 
[100 U/ml]; Sigma, batch 35H9522). After incubation the force-pCa series at 2.2 μm was 
repeated. On average force decline between the first and the last maximal control activation 
in theses series of force-pCa measurements amounted to 10±2% for cTnFL and 11±3% for 
cTnDEG exchanged cardiomyocytes before and to 15±2% for cTnFL and 12±2% for cTnDEG 
exchanged cardiomyocytes after treatment with PKA. Experiments where force decline 
exceeded 25% were discarded. As a result not all the myocytes included in this study were 
measured at all 3 experimental conditions (at sarcomere length 1.9 μm, 2.2 μm and 2.2 μm 
after the PKA). All the results obtained were divided in 2 groups: sarcomere length (n=10 
for cTnFL and n=12 for cTnDEG exchanged cardiomyocytes) and PKA treatment (n=10 for 
cTnFL and n=13 for cTnDEG exchanged cardiomyocytes) groups, each of which contained 
paired (1.9/2.2 μm and before/after PKA) measurements on the same myocytes. Maximal 
activation at 2.2 μm and pCa 4.5 was used to calculate maximal calcium-activated 
isometric force (i.e. Fmax/cross-sectional area). Maximal isometric force at sarcomere length 
1.9 μm was normalized to the cross-sectional area of the cardiomyocyte obtained at 
sarcomere length 2.2 μm. The cross-sectional area of the preparations was calculated 
assuming an elliptical shape, i.e. cross-sectional area = (width × depth × π)/ 4. Myocyte 
depth was estimated by projecting the myocyte via a small mirror, positioned at an angle of 
30°, onto the objective of the inverted microscope.122 
 
Protein analysis 
The amount of cTnI exchange was analysed as described previously in Chapter 4. 
 
Data analysis 
Force-pCa relations were fit to a Hill equation:67 
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 F(Ca2+)/F0=[Ca2+]nH/(Ca50nH +[Ca2+]nH), 
where F is steady state force at 1.9 and 2.2 μm sarcomere length. F0 denotes the steady 
force at saturating Ca2+ concentration, nH reflects the steepness of the relation, and Ca50 (or 
pCa50) represents the midpoint of the relation. 
Values are given as means ± S.E.M. of n myofibrils of myocytes. Results were 
stated to be significant based on two tailed Student’s unpaired t-tests at a level of 
significance of 0.05. 
 
 
Results 
Effect of sarcomere length on cardiomyocyte function 
Recordings of force development and images of cTnFL and cTnDEG
 
exchanged 
cardiomyocytes
 
at two different sarcomere lengths are presented in Figure 5.1 and 5.2. 
Mean dimensions (± S.E.M.) of the cTnFL (n=10) and cTnDEG (n=12) exchanged 
cardiomyocytes in sarcomere length group at a sarcomere length of 1.9 μm amounted to 
36.4±7.8 and 40.3±4.7 μm in length, 26.5±2.2 and 28.1±2.3 μm in width, respectively. 
After the force-pCa curve was determined the cardiomyocyte was stretched to 2.2 μm 
sarcomere length. At this sarcomere length mean dimensions of the cTnFL and cTnDEG 
exchanged cardiomyocytes amounted to 55.4±9.4 and 62.6±6.4 μm in length, 23.7±2.4 and 
24.3±2.5 μm in width, and 20.5±1.3 and 24.2±1.6 μm in depth, respectively. At neither 
sarcomere lengths the dimensions of the cTnFL and cTnDEG exchanged cardiomyocytes were 
significantly different. An overview of functional data is presented in Table 5.1. Maximal 
isometric force (measured at pCa 4.5) and mean passive force of both cTnFL and cTnDEG 
exchanged myocytes were increased at sarcomere length 2.2 μm compared to values 
obtained at a sarcomere length of 1.9 μm (Figure 5.3A). In addition, the Ca2+-sensitivity of 
cTnFL and cTnDEG exchanged cardiomyocytes was significantly higher at higher sarcomere 
length (pCa50: 5.44±0.02 and 5.54±0.02 for cTnFL and 5.68±0.02 and 5.81±0.02 for cTnDEG, 
at 1.9 and 2.2 μm respectively, P<0.05) (Figure 5.3B). The cooperativity of force 
development (nH) was found to be unchanged by increasing sarcomere length (Table 5.1). 
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Figure 5.1. A. Images of single cardiomyocytes with exchanged cTnFL at sarcomere length 1.9 μm, 2.2 μm and after treatment 
with PKA (at sarcomere length 2.2 μm). The bars indicate 25 µm. B. Corresponding recordings of force production in 
cardiomyocytes with exchanged cTnFL at pCa 4.5. The myocyte was slacked rapidly after force development reached a steady level 
to determine the baseline of the force transducer (zero level). After return of the myocyte into the relaxing solution (pCa 9) it was 
slacked again for 10 s to determine its passive force. 
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Figure 5.2. A. Images of single cardiomyocytes with exchanged cTnDEG at sarcomere length 1.9 μm, 2.2 μm and after treatment 
with PKA (at sarcomere length 2.2 μm) and B. Corresponding recordings of force production in the same cardiomyocytes at pCa 
4.5. For detailed description see legend of Figure 5.1. 
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Figure 5.3. A. Mean values of maximal isometric force and passive force of exchanged cTnFL and cTnDEG cardiomyocyte at 
sarcomere lengths 1.9 and 2.2 μm. Maximal (F0) and passive (Fpass) forces were obtained at saturating [Ca2+] (pCa 4.5) and at low 
[Ca2+] (pCa 9), respectively. F0 and Fpass at sarcomere length 2.2 μm of both cTnFL and cTnDEG cardiomyocyte were significantly 
higher than at 1.9 μm. Values are given as mean ± S.E.M. of 10 cTnFL cardiomyocytes and 12 cTnDEG cardiomyocytes in each 
group. B. The Ca2+-sensitivity of isometric force of exchanged cTnFL cardiomyocytes at sarcomere lengths 1.9 (open symbols) and 
2.2 (closed symbols) μm. Isometric force at submaximal activating [Ca2+] was normalized to the control force found at saturating 
[Ca2+] (pCa 4.5). The force-pCa relations are fitted to a Hill equation. ΔpCa50 was calculated by subtraction of pCa50 obtained at 1.9 
μm from pCa50 obtained at 2.2 μm for each individual cardiomyocyte and then averaging this value per group. Ca2+-sensitivity of 
cTnFL cardiomyocytes at 2.2 μm was significantly higher than at 1.9 μm (P<0.05). C. The Ca2+-sensitivity of isometric force of 
exchanged cTnDEG cardiomyocytes at sarcomere lengths 1.9 and 2.2 μm. cTnDEG cardiomyocytes at 2.2 μm were more sensitive to 
[Ca2+] than at 1.9 μm (P<0.05). Values are given as mean ± S.E.M. 
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Table 5.1. Functional data of exchanged human cardiomyocytes 
Sarcomere length PKA treatment 
Group Parameter 
1.9 μm 2.2 μm before after 
Maximal force 
(kN·m-2) 21±2 28±3 34±5 34±4 
Passive force 
(kN·m-2) 1.32± 0.33 3.04±0.51* 3.48±0.49 2.58±0.24 
pCa50 5.44±0.02 5.54±0.02* 5.52±0.02 5.44±0.01* 
cTnFL 
n=10/ 
10 
nH 3.14±0.09 2.88±0.15 2.87±0.15 2.96±0.17 
Maximal force 
(kN·m-2) 23±3 30±4 30±3 28±3 
Passive force 
(kN·m-2) 1.60±0.17 3.87±0.41* 3.53±0.47 2.77±0.27 
pCa50 5.68±0.02# 5.81±0.02*# 5.78±0.02# 5.69±0.02*# 
cTnDEG 
n=12/ 
13 
nH 2.07±0.08# 1.88±0.06# 1.94±0.07# 2.13±0.08# 
 
Abbreviations: cTnFL and cTnDEG denote cardiomyocytes exchanged with cTnFL and cTnDEG, respectively. n denote number of 
cardiomyocytes in sarcomere length/PKA- treated groups, respectively. Values are given as mean ± S.E.M. of n cardiomyocytes. 
*Significant at P<0.05, within groups 1.9 - 2.2 μm and before versus after PKA; # significant at P<0.05, cTnDEG versus cTnFL. 
 
Effect of PKA on cardiomyocyte function 
Original force recordings and images of cTnFL and cTnDEG
 
exchanged cardiomyocytes 
before and after treatment with PKA are shown in Figure 5.1 and 5.2. In the PKA treatment 
group the mean dimensions of the cTnFL (n=10) and cTnDEG (n=13) exchanged 
cardiomyocytes were 50.9±9.4 and 59.6±5.4 μm in length, 20.7±2.2 and 24±2 μm in width, 
and 18.9±1.4 and 22.5±1.3 μm in depth, respectively. Maximal isometric force and mean 
passive force were not different in cTnFL and cTnDEG exchanged myocytes (Table 5.1, 
Figure 5.4A). In both groups treatment with PKA resulted in a decrease in Ca2+-sensitivity 
(Figure 5.4B). The pCa50 values in the cTnFL group amounted to 5.52±0.02 and 5.44±0.01 
and the pCa50 in the cTnDEG group amounted to 5.78±0.02 and 5.69±0.02 before and after 
the PKA treatment, respectively, P<0.05. As can be seen in Table 5.1 the nH of cTnFL and 
cTnDEG
 
exchanged cardiomyocytes did not change after PKA treatment. 
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Figure 5.4. A. Mean values of maximal isometric force and passive force of exchanged cTnFL and cTnDEG cardiomyocytes before 
and after the treatment with PKA at 2.2 μm sarcomere length. Maximal (Fmax) and passive (Fpass) forces were obtained at saturating 
[Ca2+] (pCa 4.5) and at low [Ca2+] (pCa 9), respectively. Values are given as mean ± S.E.M. of 10 cTnFL cardiomyocytes and 13 
cTnDEG cardiomyocytes in each group. B. The Ca2+-sensitivity of isometric force of exchanged cTnFL cardiomyocytes before (open 
symbols) and after (closed symbols) the PKA treatment. Isometric force at submaximal activating [Ca2+] was normalized to the 
control force found at saturating [Ca2+] (pCa 4.5). The force-pCa relations are fitted to a Hill equation. For description of ΔpCa50 
see Figure 5.3. Ca2+-sensitivity of cTnFL cardiomyocytes after the PKA treatment was significantly lower (P<0.05). C. The Ca2+-
sensitivity of isometric force of exchanged cTnDEG cardiomyocytes before and after the PKA treatment. cTnDEG cardiomyocytes 
after the PKA treatment were less sensitive to [Ca2+] than before that (P<0.05). Values are given as mean ± S.E.M. 
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cTnDEG versus cTnFL exchanged cardiomyocytes 
At both sarcomere lengths (1.9 and 2.2 μm) and before and after phosphorylation by PKA 
the maximal isometric force and mean passive force were not significantly different 
between cTnFL and cTnDEG exchanged myocytes (Table 5.1). In contrast, a significantly 
higher Ca2+-responsiveness of force generation was observed in cTnDEG cardiomyocytes 
compared to cTnFL at both sarcomere lengths. The difference in Ca2+-responsiveness 
observed between cTnFL and cTnDEG exchanged cardiomyocytes did not differ upon 
increasing sarcomere length (ΔpCa50=0.24±0.03 and ΔpCa50=0.27±0.03 at 1.9 and 2.2 μm, 
respectively, P=0.5). This difference was also preserved upon phosphorylation with PKA at 
2.2 μm (ΔpCa50=0.26±0.03 and ΔpCa50=0.25±0.02 before and after PKA treatment, 
respectively, P=0.8). The cooperativity of force development (nH) was found to be 
significantly decreased in cTnDEG exchanged cardiomyocytes compared to cTnFL at all 
conditions (Table 5.1). 
 
Amount of exchanged troponin complex in human cardiomyocytes 
The analysis of cTnI1-192 incorporation into cardiomyocytes by Western blots using a 
specific antibody against cTnI showed that 48% of the endogenous troponin complex was 
replaced with cTnDEG. These data confirmed our previous results described in Chapter 4. 
 
 
Discussion 
The results of this study indicate that cTnI degradation at the C-terminus preserves both 
sarcomere length-dependency and protein kinase A phosphorylation signalling in human 
cardiomyocytes. More specifically, cTnI degradation did not affect (1) the increase in 
maximal force, mean passive force and the Ca2+-sensitivity of the contractile apparatus with 
an increase in sarcomere length from 1.9 to 2.2 μm and (2) the desensitisation to Ca2+ as a 
result of treatment with PKA. Thus, the ability to modulate its activity in response to 
changes in hemodynamic demands of the heart is preserved in human cardiac tissue 
containing degraded cTnI. 
The present data at a sarcomere length of 2.2 μm confirm our previous results 
(Chapter 4) on the effects of cTnI C-terminal truncation on human cardiac myofilament 
function. However, the maximal forces in this study were almost twice as large as in the 
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previous study. This difference could be due to the differences in tissue handling and 
storage (samples used in this study were stored in liquid nitrogen, while samples from the 
previous study were kept at -80°C). It is important to note that the absence of an effect on 
maximal force and the similar magnitude of the Ca2+-sensitivity shift found in cTnDEG 
exchanged cardiomyocytes compared to cTnFL preparations found in both studies suggest 
that the observed effects can be attributed solely to the degradation of cTnI and not to 
intrinsic properties of human cardiac tissue. 
 
Sarcomere –length dependency of myofilament activation 
The exact mechanism of increased Ca2+-responsiveness due to the increase in sarcomere 
length is not completely clear yet. It has been shown that affinity of cTnC to Ca2+ is 
increased with length.148,149 However, more recent experiments have shown that cTnC is 
less likely to be a crucial component in the length sensing mechanism.150 Previously, 
length-tension relationships were found to be much steeper in skinned cardiac than in 
skinned skeletal muscles and this was explained by different TnC isoforms in these 
tissues.151-153 In these recent experiments transgenic mice were developed in which fast 
skeletal TnC was expressed ectopically in the heart.150 A comparison of the length 
dependence of activation between myocytes with endogenous cTnC and myocytes 
containing primarily fast skeletal TnC revealed no difference. From this it was concluded 
that the sarcomere length dependent change in Ca2+-sensitivity of tension is independent of 
the troponin C isoform. 
Another hypothesis is that a change in sarcomere length, when volume remains 
constant, results in a change in diameter and in interfilament spacing that modulates the 
ability of crossbridges to react with the thin filament at equal Ca2+ concentrations.146 
McDonald et al.154 proposed that the likely mechanism for the change in force with 
interfilament spacing is the change in the crossbridges transition rate from weak to strong 
binding states (fapp). This change would affect the number of strongly bound force-
generating crossbridges and thus, the twitch tension at a given concentration of Ca2+. 
However, recently it has been shown that the alterations in myofilament lattice spacing may 
not be the sole mechanism that underlies the sarcomere length induced alteration of Ca2+-
sensitivity in myocardium.103 Moreover, the cooperativity of myofilament activation, which 
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can be affected by the changes in filament lattice spacing, has been shown to be also 
unchanged during the sarcomere length alterations.155 
Thin-filament proteins have been suggested to be involved in the mechanism for 
length dependent activation.141 Previously it has been shown in a transgenic mouse model 
that specific isoform switching from cTnI to slow skeletal TnI in thin myofilaments reduced 
length-dependent activation of cardiac myofilaments.147 Thus, the absence of an effect of 
cTnI degradation on sarcomere length dependency observed in this study is surprising. The 
ability of degraded cTnI to preserve the length-dependent activation of cardiac 
myofilaments and preserve the magnitude of the difference between Ca2+-sensitivity of 
cTnFL and cTnDEG cardiomyocytes at different sarcomere lengths suggests that the C-
terminal domain of cTnI is not involved in the mechanism of length dependent activation. 
Even though this part of cTnI contains actin-tropomyosin binding sites,25 the distribution of 
blocked, closed and open crossbridges at different sarcomere lengths apparently is not 
regulated by the C-domain. A significant structural difference between cTnI and slow 
skeletal TnI is that the cardiac variant possesses an additional 30 aminoacids forming an N-
terminal extension not present in the slow skeletal variant. This could be the reason for the 
observed attenuation of the length dependence of Ca2+ activation in preparations containing 
slow skeletal TnI.147 However the involvement of other protein changes, which may 
develop in transgenic animals, can not be excluded. 
The fibres from transgenic mouse hearts expressing slow skeletal TnI was found to 
be more sensitive to Ca2+ compared to wild-type controls.147 It has been suggested though 
that this can not be the reason for the smaller increase of Ca2+-sensitivity with an increase in 
sarcomere length in these preparations. This conclusion was made based on the 
experiments, in which specific isoform switching from α-TM to β-TM in the hearts of 
transgenic mice induced a sensitisation of the cardiac myofilaments to Ca2+, but did not 
alter the length dependent activation.156 Our data are in agreement with this conclusion: 
differences in cooperativity and Ca2+-sensitivity between cTnDEG and cTnFL cardiomyocytes 
were observed, but length-dependent activation was preserved. 
Evidence suggests that other proteins can determine the magnitude of shift in Ca2+-
sensitivity due to the increase in sarcomere length. The different myosin isoforms and/or 
other proteins (such as e.g. titin,157,158 myosin-binding protein C159,160 and myosin light 
chain 2161) may account for length-dependent activation rather than cTnI. 
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Effect of phosphorylation by PKA on myofilament activation 
β-Adrenergic stimulation is a major physiological mechanism to meet increases in 
circulatory demand, which acts through enhancement of systolic function as well as 
relaxation.162 Activation of PKA via this signaling pathway leads to phosphorylation of a 
several proteins within muscle cells. In skinned preparations all the membranous structures 
(plasma membrane, sarcoplasmatic reticulum) are removed, which leaves only three targets 
for PKA, myosin binding protein C (MyBP-C), cTnI and titin. It has been shown that PKA 
phosphorylation of cTnI reduces the myofilament Ca2+-sensitivity,62,142 increases Ca2+-
dissociation from cTnC163 and increases the crossbridge cycling rate and shortening 
velocity,164-167 while the maximum rate of ATP consumption remained constant.62 In this 
study a decrease in Ca2+-sensitivity of cTnFL exchanged cardiomyocytes upon PKA was 
observed, which is in agreement with our previous data obtained in human cardiac 
tissue.142,143 
Results of NMR structural studies168,169 and cross-linking studies170 support a 
mechanism in which phosphorylation of PKA sites of cTnI (Ser 23/24) triggers dissociation 
of the N-terminal region of cTnI from cTnC, inducing a reduction in affinity of cTnC for 
Ca2+ and a decrease in Ca2+ -sensitivity of the myofilaments. It has been shown that 
phosphorylation of Ser 23/24 causes cTnI to become more compact.171 Moreover, 
fluorescence resonance transfer revealed that phosphorylation of these serine sites causes a 
decrease in the mean distance between the N- and C-terminal regions of cTnI172 and an 
increase in helicity of the backbone structure.144 It was hypothesized that this 
conformational change involves bending of the cTnI N-terminus such that Ser23/24 
phosphorylation destabilizes the interaction between the N-terminus of cTnI and the 
regulatory region of cTnC173 and this in turn probably destabilizes Ca2+-binding to cTnC. 
The C-terminus of cTnI (residue 206 in particularly) was shown to be important 
for the structural responsiveness of cTnI upon phosphorylation.144 Thus, the preservation of 
PKA induced desensitisation of myofilaments observed in this study was somewhat 
unexpected. The explanation for this might be the existence of structural alterations inside 
the troponin complex in cardiac myofilament, which compensate for the loss of the cTnI C-
terminus and preserve its function. 
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Implications for the in vivo function 
Our results suggest that β-adrenergic responsiveness and length-dependency of the 
cardiomyocytes is not affected by C-terminal truncation of cTnI. The amount of exchange 
in our setting was about 50%, while the highest degree of cTnI degradation found in 
humans is about 26%.46 This suggests that the effect of cTnI1-192 in vivo will be less 
compared to what was found here. However, even though cTn complex of patients with 
ischemic cardiomyopathy will be able to modulate the heart function upon an increase in 
hemodynamic demands (such as during physical exercise or stress), the Ca2+-sensitivity of 
filament contraction in these hearts will be still increased compared to healthy cardiac 
tissue. This might still contribute to the diastolic dysfunction and ultimately heart failure in 
these patients. 
It is tempting to speculate that selective C-terminal proteolysis of cTnI induces a 
feed-forward activation loop in the progression of ischemia related human 
cardiomyopathies (Figure 5.6). 
 
Figure 5.6. Role of cTnI degradation in induction and development of heart failure after ischemia. 
 
Ca2+ overload induced by ischemia/reperfusion leads to an activation of the Ca2+-
dependent protease calpain-1. It has been shown that this protease induces specific C-
terminus degradation of cTnI.109 The cTnI1-192 alters cardiac myofilament activation by an 
increase of Ca2+-sensitivity and by slowing both activation and relaxation kinetics (Chapter 
4). This results in prolonged relaxation of human myocardium and leads to diastolic 
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dysfunction, which in turn may cause left ventricular hypertrophy.92,174,175 The contractility 
of myocardium can be modulated by β-adrenergic signaling pathway or increased preload 
(denoted as opposing factors in Figure 5.6), however it will not be able to completely 
compensate for the loss of muscle contractility. It has been shown that mechanical stress 
increases cytosolic Ca2+ levels in neonatal rat cardiomyocytes176 and this may induce 
further activation of calpain-1. Certainly, there are many more cellular processes involved 
in the development of ischemic cardiomyopathy. They were not mentioned here to 
highlight this particular component within a more general framework. This scheme 
specifically points out the role of cTnI degradation in the development of ischemic 
cardiomyopathy and may explain how chronic depletion of cTnI from viable remodelled 
myocardium after myocardial infarction may lead to a global contractile dysfunction as 
observed in pigs.111 However, the relative contribution of cTnI selective proteolysis into 
induction and progression of human ischemic cardiomyopathy remains to be established. 
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Summary 
Alterations of contractile proteins occur in human heart failure. They include both changes 
in protein expression (translational modifications) and modulation by phosphorylation and 
degradation of the proteins (post-translational modifications). These changes may have a 
beneficial effect in order to maintain pump function of diseased myocardium. They can also 
be detrimental and substantially contribute to the progression of contractile dysfunction of 
failing human heart. Hence, a new therapeutic strategy should take into account the 
functional consequences of compensatory and/or detrimental contractile protein changes 
that occur during heart failure. Therefore, it is of a great importance to reveal contractile 
protein alterations in human heart failure and their influence on the functional properties of 
human cardiac tissue. 
In this thesis, mechanical and energetic consequences of the contractile protein 
changes, which occur during heart failure were studied in human healthy and failing 
myocardial tissue. Isometric force development and ATP consumption at different calcium 
concentrations were measured in chemically skinned atrial trabeculae and ventricular 
muscle strips to reveal the effect of MHC isoform changes. The effect of cTnI degradation 
on isometric force development and force activation and relaxation kinetics was studied 
using cardiac myofibrils and cardiomyocytes. Manipulation of troponin composition in 
human cardiac preparations was achieved by replacement of endogenous cTn complex by 
an exogenous troponin complex containing truncated cTnI. Contractile protein isoform 
composition was determined by one-dimensional SDS-gel electrophoresis, while 
phosphorylation status of proteins was obtained using specific phospho-antibodies in 
Western immunoblotting. Protein composition was correlated with functional properties of 
human cardiac tissue to determine if and to what extent protein changes are beneficial or 
detrimental for human cardiac pump function. 
 
In Chapter 1, an introduction to the background and methods of this study is 
given. The aim of this research is defined. 
In Chapter 2, the relation between contractile properties and MHC isoform 
composition in healthy human myocardium was determined. One-dimensional SDS-PAGE 
revealed that in ventricular tissue the β-MHC isoform predominated, whereas in atrial 
tissue a variable mixture of α- and β-MHC was found. Force development in ventricular 
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tissue was about 5-fold more economical, but 9 times slower, than in atrial tissue. 
Significant linear correlations were found between MHC isoform composition, ATP 
consumption and rate of force redevelopment. These correlations suggest that the increased 
economy and decreased speed of contraction found in ventricular tissue as compared to 
atrial tissue can be attributed to the prevalence in this tissue of the β-MHC isoform. 
The rate of ATP consumption of preparations with pure (100%) α-MHC was 
approximately 5 times higher than the rate in preparations with pure β-MHC (0.181±0.018 
and 0.039±0.014 mmol⋅l-1⋅s-1, respectively, for extrapolated values ± their standard errors). 
The KTR associated with pure α-MHC expression calculated from the regression line (10.8 
s-1) was considerably higher than the values obtained in ventricular tissue (0.9 s-1). These 
results indicate that even a small shift in MHC isoform expression may have a considerable 
impact on cardiac performance in human tissue. 
Histochemical analysis revealed that the average density of myofibrillar tissue was 
significantly lower in atrial than in ventricular preparations (50±9 and 89±2%, 
respectively). The difference in the percentage of interstitial space in atrial (20±4%) and 
ventricular (11±2%) tissue did not reach statistical significance (P=0.09). The correction of 
the data for the proportion of myofibrillar tissue abolished the difference in maximal 
tension, increased the difference in ATPase activity and slightly enhanced the relative 
difference in the extrapolated ATPase-values of the “pure” isoforms. It also slightly 
improved the correlation between ATPase activity and β-MHC composition. This 
difference in the average density of myofibrillar tissue between atrial and ventricular 
preparations and atrial intra-trabeculae variability should be taken into consideration in 
studies, where these preparations are used. 
In Chapter 3, the relation between functional properties and MHC isoform 
composition in diseased human myocardium was studied. Chronic atrial fibrillation was 
accompanied by a significant shift from the fast α-MHC isoform to the slow β-MHC 
isoform compared to the MHC isoform composition in tissue from patients with sinus 
rhythm (β-MHC content shifted from 24.6±3.2 to 38.1±5.7% of total MHC). On the other 
hand, both donor and end-stage failing ventricular tissue contained almost exclusively β-
MHC isoform: only in two donors and one failing heart sample the α-MHC isoform was 
detected. The economy of contraction and other functional properties were all preserved in 
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atrial fibrillation and in end-stage human heart failure. However, Ca2+-sensitivity of ATP 
consumption was significantly higher in AF than in SR patients, while Ca2+-sensitivity of 
force did not differ. This implies that tension cost of atrial contraction in AF patients 
decreases with an increase in Ca2+ concentration. In failing ventricular tissue Ca2+-
sensitivity of both force and ATP consumption were increased compared to non-failing 
donors. 
The increase in β-MHC content of healthy and diseased cardiac tissue correlated 
with a decrease in ATP consumption and in tension cost. From these correlations it appears 
that the shift in MHC composition towards the β-MHC isoform may be beneficial under 
pathological conditions, since less energy is required to maintain pump function. Because 
human ventricular tissue mainly consists of β-MHC, this shift is of less importance in 
ventricles, but it is a prominent feature of failing atria. 
Histochemical analysis revealed the percentage of interstitial space (mainly 
occupied by connective tissue) in both non-failing atrial and ventricular tissue was lower 
than in diseased tissue. Thus development of fibrosis can also contribute to reduced pump 
function of failing human myocardium (Chapter 1, Figure 1.1). 
In Chapter 4, the functional implications of cTnI degradation were investigated in 
human cardiac tissue. Endogenous cTnI was replaced by the primary degradation product 
of cTnI (cTnI1-192) or by full length cTnI
 
in both cardiac myofibrils and cardiomyocytes. 
Maximal tension was not affected, while the rates of force activation and redevelopment as 
well as relaxation kinetics were slowed in the presence of truncated cTnI. Ca2+-sensitivity 
of the contractile apparatus was increased in preparations containing cTnI
1-192 complex 
compared to full-length exchanged cardiomyocytes. These results indicate that degradation 
of cTnI in human myocardium will mainly impair diastolic function. 
In Chapter 5, the effect of cTnI degradation on myofilament responsiveness to β-
adrenergic stimulation and to increased preload (Frank-Starling effect) was investigated in 
human cardiomyocytes. PKA-mediated desensitisation and sarcomere length dependent 
increase in force-generating capacity of myofilaments were preserved in cTnI1-192 
exchanged cardiomyocytes. This indicates that cTnI degradation does not affect β-
adrenergic and preload-dependent responses in human myocardium. 
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Conclusions 
1. Myocardial contraction is 5-fold more economical in ventricular than in atrial human 
tissue. 
The 5-fold difference in economy of contraction results from decreased ATP consumption 
of ventricular tissue, since no significant difference in isometric force per cross-sectional 
area was observed between atrial and ventricular preparations. This functional difference 
should be taken into account during extrapolation of results obtained on ventricular tissue to 
the properties of atrial tissue and vice versa. 
 
2. Human β-MHC isoform is 5 times more economical, but considerably slower than α-
MHC isoform. 
From the correlation between the rate of ATP consumption and MHC composition, the rate 
of ATP consumption of fibres with pure α-MHC and pure β-MHC isoforms could be 
calculated. The decreased tension cost value of fibres with 100% β-MHC isoform results 
from a decreased rate of ATP consumption, since no correlation between isometric force 
per cross-sectional area and β-MHC isoform content was observed. 
 
3. Under pathological conditions the shift in MHC composition towards the β-MHC 
isoform may be beneficial in human atrial tissue, but plays little or no role in ventricular 
tissue. 
Since β-MHC isoform is more economical than α-MHC, the increased content of β-MHC 
in cardiac muscle fibres will be beneficial for failing human heart, because less energy will 
be required to maintain pump function. It should be noted however that under severe 
cardiovascular stress the MHC isoform shift might become disadvantageous since cardiac 
reserve required at this conditions largely determined by the rate of myocardial contraction, 
which will be considerably slowed with the increased content of β-MHC. These effects are 
mostly characteristic to atrial tissue, since healthy atrial tissue contains only about 25% of 
β-MHC. Hence, the MHC isoform shift observed during cardiac disease (e.g. atrial 
fibrillation) will exert a large functional effect. Human ventricular tissue mainly consists of 
β-MHC (up to 100%). Thus the MHC isoform shift, which may occur in some individuals, 
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will be considerably smaller than in atria and hence will have less effect on myocardial 
pump function. 
 
4. The direct effect of changes in troponin composition on functional properties of human 
cardiac tissue can be assessed by exchange of modified troponin complex into cardiac 
human preparations. 
As it has been shown with digital imaging microscopy, the protocol used for the exchange 
of troponin complex into human cardiomyocytes ensures its uniform exchange into the 
cardiomyocytes. At the given conditions the exchanged cardiomyocytes develop isometric 
force comparable to the non-exchanged cardiomyocytes and remain stable during the 
application of a whole range of sub-maximal calcium activations. This makes the exchange 
an excellent technique to study the specific functional effect of both translational and post-
translational modifications of cardiac troponin subunits in human cardiac tissue. 
 
5. Degradation of cTnI from its C-terminus may contribute to diastolic dysfunction in 
human myocardium. 
Maximal tension was not affected after the exchange of cTnI1-192 containing troponin 
complexes into human cardiac myofibrils and cardiomyocytes, which indicated that systolic 
function was not affected by degradation of cTnI. The slowing of relaxation and activation 
kinetics and increased Ca2+-sensitivity of the contractile apparatus in preparations 
containing cTnI
1-192 indicates that degradation of cTnI might rather impair diastolic 
function and in this way contribute to development of heart failure in humans. 
 
6. Cardiac TnI degradation does not affect β-adrenergic and preload-dependent responses 
in human myocardium. 
PKA-mediated desensitisation and sarcomere length dependent increases in force-
generating capacity of the myofilaments were preserved in the cTnI1-192 exchanged 
cardiomyocytes. This indicates that the response to cardiovascular stress (e.g. as observed 
during exercise) will not be blunted in human hearts containing degraded cTnI. 
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In brief, in this thesis it has been shown to what extent MHCs determine the energetic 
properties of human cardiac tissue and cTnI is shown to play a pivotal role in determining 
its Ca2+-sensitivity. 
 
 
Future directions 
Oxidation of contractile proteins 
Oxidative stress has been assigned an important role in reducing myocardial function 
during heart failure.177,178 Oxidation is another type of myofilament protein post-
translational modification, and represents a new topic in the research on altered 
myofilament function in diseased human heart. The major reactive oxygen species (ROS) 
and their derivatives, reactive nitrogen species (RNS) are superoxide radicals (O2⎯ •), 
hydroperoxyl radicals (HO2•), nitric oxide (NO) and peroxynitrite (ONOO⎯). Collectively, 
these radicals cause a loss of biological function of contractile proteins through oxidation of 
the protein backbone and/or amino acid side chains, which may lead to protein 
fragmentation and the formation of the protein-protein cross-linkages, respectively. Recent 
evidence suggests an important role for oxidative stress during atrial fibrillation in 
humans.93,179 Mihm et al.93 showed an increased prevalence of contractile protein oxidation, 
nitration and carbonyl formation in patients with AF. The important role of myocardial 
NAD(P)H oxidase activation and NO-synthase uncoupling has been demonstrated in 
patients with paroxysmal and permanent AF.179 
In addition, detrimental consequences of contractile protein oxidation have been 
implicated in ischemia/reperfusion injury.180,181 Some time ago ROS–induced damage to 
myofibrillar proteins has been proposed as a important mechanism underlying contractile 
dysfunction observed during myocardial stunning.182 However, only recently a start has 
been made in the identification of contractile proteins affected by oxidation. It has been 
shown in rat hearts that actin undergoes the major changes as a result of postischemic 
reperfusion.180 In an experimental model of coronary microembolization in dogs and pigs, 
the contractile dysfunction was related to reversible oxidation of tropomyosin.181 Moreover, 
it has been shown that addition of superoxide anion or peroxynitrite to cardiac muscle 
preparations reduced or even completely abolished maximal calcium-activated force via 
post-translational modification of myofilament proteins.183-185 
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These studies point towards an important role for contractile protein oxidation in 
cardiac dysfunction. Hence, prevention of protein oxidation may preserve or even increase 
myocardial contractility in human heart failure. The use of general antioxidants in multiple 
clinical trials did not prove to be beneficial.186 However, a selective approach directed 
against specific target proteins and specific ROS/RNS radicals may demonstrate positive 
results. Thus, future research on the effect of myofibrillar protein oxidation on functional 
properties of human failing myocardium is very promising. 
 
Future treatment approaches of heart failure  
Heart failure imposes a high risk of repeated hospitalisation and death in the human 
population. Despite the clear benefit of current therapies the mortality in this syndrome 
remains high. Therefore the search for new therapies has a high priority. 
New targeted therapies that would increase or maintain contractility by selective 
modulation of specific target proteins represent an important research area. One possible 
therapy is to alter the expression of proteins using gene transfer. Recently it has been shown 
that expression of the βARKct (a peptide inhibitor of the β-adrenergic receptor kinase) via 
adenovirus-mediated gene transfer can improve contractile function and β-adrenergic 
responsiveness in failing human myocytes.187 Also, it has been shown that adenoviral gene 
transfer of antisense phospholamban (asPL), which decreases the inhibitory effects of 
phospholamban on SERCA2a can improve contractile function in failing human 
myocardium.188 Unlike inotropic agents that improve contractile function at the expense of 
increased mortality and worsening metabolism it has been shown that gene transfer of 
SERCA2a improves survival and the energy potential in failing rat hearts.189 Thus, 
targeting of specific myofilament proteins may provide therapeutic benefits in human heart 
failure. 
In the first part of this thesis it has been shown that increased expression of β-
MHC in human heart failure improves the myofilament energetics and therefore may be of 
great help for the cardiac pump function. Whether it would be beneficial to induce a further 
shift in MHC composition is doubtful. Since at the same time it would significantly 
decrease the speed of myocardial contraction, the response to cardiovascular stress (e.g. 
physical activity) in patients would become severely impaired. Recently this has been 
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demonstrated in transgenic mice with almost complete replacement of the normally 
predominant α-MHC isoform with β-MHC.85 
 
Apart from reversal of translational protein changes, post-translational alterations 
might be easy to target with therapy and should become a primary focus for the 
development of new interventional strategies. The effect of cTnI C-terminal degradation 
investigated in the last part of this thesis is clearly detrimental. Therapies directed on 
reduction of the cTnI proteolysis may improve the depressed contractility after ischemia 
and prevent development of heart failure in humans. The first indication that inhibition of 
calpain-1 (the protease, which induces cTnI degradation) indeed reduces contractile 
dysfunction upon ischemia/reperfusion injury has been obtained in rats.190 An alternative 
approach to prevent cTnI degradation is via modulation of its phosphorylation status. In 
vitro studies have shown that protein kinase A-mediated cTnI phosphorylation protects 
cTnI from degradation,108 while phosphorylation by protein kinase C enhances 
degradation.191 Investigation of the effect of commonly used medication, which could 
increase cTnI phosphorylation by PKA (β-blockers) and decrease phosphorylation by PKC 
(ACE-inhibitors) on recovery of myocardial pump function is currently performed within a 
collaborative project in a pig model of myocardial infarction (Laboratory for Physiology, 
VUmc, Amsterdam & Experimental Cardiology, Thoraxcenter and Department of 
Biochemistry, Erasmus MC, Rotterdam). Further experiments are required to test the 
feasibility of both these approaches in human myocardium. 
The questions addressed in this thesis provide an insight into the cellular 
pathomechanisms of depressed contractility in human heart failure. The information about 
the role of MHC isoforms and cTnI obtained in these studies is important for the 
development of new protein targeted therapeutic interventions, which will improve 
treatment and decrease mortality of heart failure in humans. 
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Samenvatting 
Hartfalen wordt bij mensen onder meer gekenmerkt door veranderingen in contractiele 
eiwitten van de hartspier. Deze veranderingen kunnen zowel optreden op het niveau van 
eiwitexpressie (translationele modificatie) als op het niveau van modulatie, door middel van 
fosforylering en degradatie van eiwitten (post-translationele modificatie). Deze processen 
kunnen een gunstig effect hebben op de functie van het falende hart, maar soms dragen ze 
juist bij aan de progressie van de contractiele disfunctie. Het is erg belangrijk om meer te 
weten te komen over de functionele consequenties van compensatoire en/of schadelijke 
veranderingen in de contractiele eiwitten tijdens de ontwikkeling van hartfalen, zodat met 
deze kennis nieuwe therapeutische strategieën ontwikkeld kunnen worden. 
In dit proefschrift worden in gezond en falend humaan hartspierweefsel de 
mechanische en energetische consequenties bestudeerd van veranderingen in contractiele 
eiwitten die optreden tijdens hartfalen. Stukjes spierweefsel afkomstig van de kamer en 
trabekels, afkomstig van de boezem zijn chemisch ontdaan van hun membraan. De 
isometrische contractiekracht en ATP-consumptie is gemeten bij verschillende 
calciumconcentraties, om zo het effect te bepalen van veranderingen in de isoform van de 
zware keten van myosine (MZK; myosin heavy chain, MHC). In myofibrillen en 
cardiomyocyten is het effect van degradatie van troponine I (cTnI) op isometrische 
contractiekracht, krachtsactivatiekinetiek en krachtrelaxatiekinetiek ook bestudeerd. In deze 
studie werd de samenstelling van het troponine in de humane hartspierpreparaten 
gemanipuleerd door het endogene troponine-complex te vervangen door een exogeen 
complex dat getrunceerd troponine bevatte. De isoform van het contractiele eiwit werd 
bepaald met behulp van eendimensionale SDS-gelelectroforese, en voor het bepalen van de 
mate van fosforylering van de eiwitten werd gebruik gemaakt van specifieke fosfo-
antilichamen in een Western blot. De eiwitsamenstelling werd gecorreleerd met de 
functionele eigenschappen van het humane hartspierweefsel, om zo te bepalen of – en in 
welke mate – veranderingen in deze eiwitten een gunstig of schadelijk effect hebben op de 
pompfunctie van het hart. 
 
Hoofdstuk 1 bevat een introductie over de achtergrond en de methoden van deze 
studie. Het doel van dit onderzoek wordt gedefinieerd. 
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In Hoofdstuk 2 wordt de relatie tussen contractiele eiwitten en MZK isoform 
compositie in gezond humaan hartspierweefsel bepaald. Eendimensionale SDS-PAGE 
toonde aan dat in weefsel afkomstig van de hartkamer vooral β-MZK voorkomt, terwijl 
weefsel afkomstig van de boezems verschillende verhoudingen van zowel α- als β-MZK 
bevat. De krachtsontwikkeling in kamerweefsel was ongeveer vijf keer meer economisch, 
maar negen keer trager dan in boezemweefsel. Er bestonden significante lineaire correlaties 
tussen MZK isoform compositie, ATP consumptie, en de tijd van herontwikkelen van de 
kracht (KTR). Dit suggereert dat de toegenomen economie en afgenomen snelheid van de 
contractie in het spierweefsel van de hartkamer ten opzichte van die in de boezems, 
toegeschreven kan worden aan de hogere prevalentie van de β-isoform in de kamers. 
De ATP-consumptie van preparaten die voor 100% uit α-MZK bestonden was 
ongeveer vijf keer hoger dan die van preparaten die alleen β-MZK bevatten (0.181±0.018 
and 0.039±0.014 mmol⋅l-1⋅s-1, respectievelijk, voor geëxtrapoleerde waarden ± hun 
standaardfouten). De KTR geassocieerd met pure α-MZK expressie berekend van de 
regressielijn (10.8 s-1) was aanzienlijk hoger dan de waarden verkregen in kamerweefsel 
(0.9 s-1). Dit betekent dat zelfs een kleine verschuiving in MZK isoform expressie aan 
aanzienlijke impact kan hebben op het functioneren van het humane hart. 
Histochemische analyse toonde aan dat de gemiddelde dichtheid van myofibrillair 
weefsel significant lager was in boezemweefsel dan in kamerweefsel (50±9 and 89±2%, 
respectievelijk). Het verschil in het percentage interstitiële ruimte in boezem- (20±4%) en 
kamer- (11±2%) weefsel was niet statistisch significant (p=0.09). Na correctie van de data 
voor de proportie myofibrillair weefsel verdween het verschil in maximale tensie, nam het 
verschil in ATPase activiteit toe, en nam het relatieve verschil in de geëxtrapoleerde 
ATPase-waarden van de “pure” isovormen licht toe. Ook verbeterde de correlatie tussen 
ATPase activiteit en β-MZK compositie. Met dit verschil in gemiddelde dichtheid van 
myofibrillair weefsel tussen preparaten afkomstig uit boezem- en kamerweefsel, evenals 
met de variabiliteit in atriale trabekels, zou rekening moeten worden gehouden in studies 
waarbij van deze preparaten gebruik wordt gemaakt. 
In Hoofdstuk 3 is de relatie tussen functionele eigenschappen en MZK isoform 
compositie in ziek humaan hartweefsel bestudeerd. Chronisch boezemfibrilleren ging 
gepaard met een significante verschuiving van de snelle α-isoform naar de trage β-isoform, 
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vergeleken met de MZK isoform compositie in weefsel van patiënten met sinusritme (het 
percentage β-MZK verschoof van 24.6±3.2 naar 38.1±5.7% van het totale MZK). Zowel 
kamerweefsel van donoren als kamerweefsel van patiënten met eind-stadium hartfalen 
bevatte daarentegen vrijwel uitsluitend β-MZK: de α-MZK isoform was slechts in twee 
donorharten en een falend hart aantoonbaar. De economie van de contractie evenals de 
overige functionele eigenschappen waren niet afgenomen bij boezemfibrilleren en eind-
stadium hartfalen. De Ca2+-gevoeligheid van de ATP-consumptie was daarentegen 
significant hoger in patiënten met boezemfibrilleren dan in mensen met sinusritme, terwijl 
de Ca2+-gevoeligheid van de kracht niet verschillend was. De tension cost (ATP verbruik 
gedeeld door de kracht) van de boezemcontractie in patiënten met boezemfibrilleren neemt 
dus af met een toename van de Ca2+ concentratie. In kamerweefsel van patiënten met 
hartfalen zijn de Ca2+-gevoeligheid van zowel kracht als ATP-consumptie toegenomen 
vergeleken met donoren zonder hartfalen. 
De toename in β-MZK in gezond en ziek hartspierweefsel correleerde met een 
afname van de ATP-consumptie en tension cost. Uit deze correlaties kan men opmaken dat 
de verschuiving in β-MZK isoform gunstig is onder pathologische omstandigheden, 
aangezien hij leidt tot een afname van de benodigde energie voor het behoud van de 
pompfunctie. Deze verschuiving is minder belangrijk in kamers, omdat humaan 
kamerweefsel vooral uit β-MZK bestaat, maar dit proces is wel een prominent kenmerk van 
falende boezems. 
Histochemische analyse toonde aan dat het percentage interstitiële ruimte (die 
vooral bindweefsel bevat) in niet-falend boezem- en kamerweefsel lager was dan in ziek 
weefsel. De ontwikkeling van fibrose kan dus ook bijdragen aan de afgenomen 
pompfunctie van falend humaan hartspierweefsel (Hoofdstuk 1, Figuur 1.1). 
In Hoofdstuk 4 zijn de functionele gevolgen van cTnI degradatie in humaan 
hartweefsel bestudeerd. In zowel myofibrillen als in cardiomyocyten werd endogeen cTnI 
vervangen door het primaire degradatieproduct van cTnI (cTnI1-192), of door compleet cTnI. 
Dit had geen invloed op de maximale tensie, terwijl de snelheid van krachtsactivatie en 
KTR, evenals de relaxatie, trager waren in de aanwezigheid van getrunceerd cTnI. De Ca2+-
gevoeligheid van het contractiele apparaat was toegenomen in preparaten die cTnI
1-192 
bevatten, vergeleken met cardiomyocyten waarin endogeen cTnI was uitgewisseld tegen 
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compleet cTnI. Dit betekent dat cTnI degradatie in humaan hartspierweefsel vooral een 
schadelijke invloed zal hebben op de diastolische functie van het hart. 
Het effect van cTnI degradatie op de gevoeligheid van myofilamenten voor β-
adrenerge stimulatie en een toegenomen voorbelasting (het Frank-Starling effect) in 
humane cardiomyocyten wordt beschreven in Hoofdstuk 5. PKA-gemedieerde 
desensitisatie en sarcomeerlengte-afhankelijke toename in de kracht-opwekkende capaciteit 
van myofilamenten waren niet afgenomen in cardiomyocyten waarin endogeen cTnI was 
uitgewisseld tegen cTnI1-192. Dit betekent dat cTnI degradatie geen invloed heeft op β-
adrenerge en voorbelasting-afhankelijke responsen van humaan hartspierweefsel. 
 
Conclusies 
1. In humane harten is de contractie van de hartspier vijfmaal meer economisch in 
kamerweefsel dan in boezemweefsel. 
Het vijfvoudige verschil in economie van de contractie is het gevolg van een afgenomen 
ATP consumptie in kamerweefsel, aangezien tussen boezem- en kamerpreparaten geen 
significant verschil werd gezien in de isometrische kracht gecorrigeerd voor cross-
sectioneel oppervlak. Dit functionele verschil moet in aanmerking worden genomen als 
resultaten verkregen in kamerweefsel worden geëxtrapoleerd naar boezemweefsel, of vice 
versa. 
 
2. De humane β-MZK isoform is vijfmaal meer economisch, maar aanzienlijk trager dan 
de α-MZK isoform. 
Uit de correlatie tussen de mate van ATP-consumptie en MZK-compositie kon de mate van 
ATP-consumptie van vezels met alleen α-MZK en alleen β-MZK isovormen worden 
berekend. De afgenomen tension cost waarde van vezels met 100% β-MZK is het gevolg 
van een afgenomen ATP-consumptie, aangezien geen correlatie tussen de isometrische 
kracht gecorregeerd voor cross-sectioneel oppervlak en de hoeveelheid β-MZK werd 
gezien. 
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3. Onder pathologische omstandigheden lijkt de verschuiving in MZK samenstelling naar 
de β-MZK isoform gunstig te zijn in boezemweefsel, maar deze speelt hooguit een kleine rol 
in kamerweefsel. 
Aangezien de β-MZK isoform meer economisch is dan de α-isoform, zal een toename van 
de hoeveelheid β-MZK in hartspiervezels gunstig zijn voor een falend humaan hart, omdat 
minder energie nodig zal zijn voor het in stand houden van de pompfunctie. Hierbij moet 
echter wel opgemerkt worden dat de MZK isoform verschuiving ongunstig kan worden ten 
tijde van zware cardiovasculaire belasting. De cardiale reserve die in deze omstandigheden 
nodig is, hangt namelijk in belangrijke mate af van de snelheid van de contractie, en deze 
neemt aanzienlijk af bij een toename van de hoeveelheid β-MZK. Deze effecten treden 
vooral op in boezemweefsel, aangezien gezond boezemweefsel slechts 25% β-MZK bevat. 
De MZK isoform verschuiving die wordt gezien bij hartziekten (bijvoorbeeld 
boezemfibrilleren) zal in de boezems dus een groot functioneel effect hebben. Humaan 
kamerweefsel bestaat vooral uit β-MZK (tot 100%). De MZK isoform verschuiving die in 
sommige patiënten zal optreden zal in de kamers dus aanzienlijk kleiner zijn, en daardoor 
zal het effect op de pompfunctie van het hart beperkt zijn. 
 
4. Het directe effect van de samenstelling van troponine op de functionele eigenschappen 
van humaan hartweefsel kan worden bepaald door gemodificeerd troponine complex uit te 
wisselen tegen “endogeen” troponine in humane hartspierpreparaten. 
Digital imaging microscopy liet zien dat de uitwisseling van een “exogeen” troponine 
complex tegen endogeen troponine in de hartspiercellen uniform was. Onder de geldende 
condities ontwikkelen de uitgewisselde hartspiercellen een isometrische kracht die 
vergelijkbaar is met niet-uitgewisselde hartspiercellen, en blijven de cellen stabiel 
gedurende het toedienen van een uitgebreide serie sub-maximale calcium-activaties. Dit 
maakt deze uitwisselingstechniek uitermate geschikt om de specifieke functionele effecten 
van zowel translationele als post-translationele modificaties van cardiale troponine subunits 
te bestuderen in humaan hartweefsel. 
 
5. Degradatie van cTnI aan de C-terminale zijde draagt mogelijk bij aan diastolische 
dysfunctie in het humane hart. 
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Uitwisseling van cTnI1-192-bevattende troponine complexen in humane cardiale 
myofibrillen en hartspiercellen had geen invloed op de maximale spanning. Dit duidt erop 
dat de systolische functie niet beïnvloed werd door cTnI degradatie. De vertraagde relaxatie 
en activatiekinetica, evenals de toegenomen Ca2+-gevoeligheid van het contractiele apparaat 
in cTnI
1-192-bevattende preparaten wijst er op dat cTnI degradatie eerder een schadelijke 
invloed heeft op de diastolische functie, en op die manier een bijdrage levert in de 
ontwikkeling van hartfalen bij mensen. 
 
6. Cardiale cTnI degradatie heeft geen invloed op β-adrenerge en voorbelasting-
afhankelijke responsen in humaan hartspierweefsel. 
PKA-gemedieerde desensitisatie, evenals de sarcomeerlengte-afhankelijke toename van de 
kracht-genererende capaciteit de myofilamenten was onveranderd in hartspiercellen met 
cTnI1-192. Dit wijst erop dat de respons op cardiovasculaire stress (zoals bijvoorbeeld tijdens 
lichamelijke inspanning) niet verminderd zal zijn in humane harten die gedegradeerd cTnI 
bevatten. 
 
Kort samengevat wordt in dit proefschrift beschreven in welke mate MZKs de energetische 
eigenschappen van humaan hartweefsel beïnvloeden, en wordt aangetoond dat cTnI van 
grote invloed is op de Ca2+-gevoeligheid. 
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Короткий зміст 
Під час серцевої недостатності в серці людини відбуваються зміни в скоротливих 
білках. Вони включають як зміни в синтезі білків (трансляційні модифікації), так і 
регуляцію фосфорилюванням і деградацією білків (пост-трансляційні модифікації). 
Ці зміни можуть мати сприятливий характер і підтримувати скоротливу функцію 
хворого міокарду. Вони можуть бути також несприятливими і в значній мірі сприяти 
розвитку скоротливої дисфункції хворого серця людини. Таким чином нові 
терапевтичні засоби мають приймати до уваги функціональні наслідки 
компенсаційних і/або згубних змін в скоротливих білках, що відбуваються під час 
серцевої недостатності. Тому дуже важливо дослідити зміни в скоротливих білках під 
час серцевої недостатності у людини, а також їх вплив на функціональні властивості 
людської серцевої тканини. 
В даній дисертації механічні і енергетичні наслідки змін в скоротливих 
білках, що відбуваються під час серцевої недостатності, були дослідженні в здоровій 
і хворій тканині міокарду людини. Для того, щоб визначити ефект зміни складу 
ізоформ важких ланцюгів міозину (ВЛМ; myosin heavy chain, MHC), розвиток 
ізометричної сили і споживання АТФ при різних концентраціях кальцію були 
виміряні в хімічно скінованих трабекулах передсердя і м’язових смужках шлуночка. 
Наслідки деградації серцевого тропоніну І (сТнІ; cTnI) для розвитку ізометричної 
сили та кінетики активації і розслаблення напруження були досліджені 
використовуючи серцеві міофібрили і міоцити. Модуляція складу тропоніну в 
людських серцевих препаратах була досягнена заміною ендогенного тропонінового 
комплексу екзогенним тропоніновим комплексом, що містив усічений сТнІ. Склад 
ізоформ скоротливих білків був визначений за допомогою одновимірного 
содіумдодецил сульфат (СДС) - гель електрофорезу, в той час як стан 
фосфорилювання білків був визначений Вестерн іммуноблотінгом використовуючи 
спеціальні фосфо-антитіла. Для того, щоб визначити якість та міру сприятливості 
змін в білках для скоротливої функції серця людини склад білків був співвіднесений 
з функціональними властивостями людської серцевої тканини. 
 
В Главі 1 представлено загальний вступ і методи, використані в даній 
роботі. Визначено цілі дослідження. 
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В Главі 2 розглянуто взаємовідносини між скоротливими властивостями і 
складом ізоформ ВЛМ у здоровому міокарді людини. За допомогою одновимірного 
СДС-поліакріламідного гель електрофорезу (СДС-ПААГ) було визначено, що в 
тканині шлуночка переважає ізоформа β-ВЛМ, в той час як в тканині передсердя 
було знайдено мінливу суміш ізоформ α- і β-ВЛМ. Розвиток сили в тканині 
шлуночка був в 5 разів економніший, але в 9 разів повільніший, ніж у тканині 
передсердя. Було знайдено суттєві лінійні кореляції між вмістом ізоформ ВЛМ, 
споживанням АТФ і швидкістю повторного розвитку сили. Дані кореляції вказують 
на те, що підвищена економія і знижена швидкість скорочення в тканині шлуночка в 
порівнянні з тканиною передсердя, можуть бути викликані переважанням в цій 
тканині ізоформи β-ВЛМ. 
Швидкість споживання АТФ у препаратах, що містили “чистий” (100%) α-
ВЛМ, був приблизно в 5 разів вище, ніж швидкість у препаратах, що містили 
“чистий” β-ВЛМ (0.181±0.018 і 0.039±0.014 ммоль⋅л-1⋅с-1, відповідно, для 
екстрапольованих значень ± їх стандартні похибки). КТР (швидкість повторного 
розвитку сили), що відповідає “чистому” α-ВЛМ і розраховується з лінії регресії 
(10.8 с-1) була значно вища, ніж відповідна величина отримана для тканини шлуночка 
(0.9 с-1). Ці результати вказують на те, що навіть невеликий зсув у вмісті ізоформ 
ВЛМ може мати значний вплив на роботу серця людини. 
За допомогою гістохімічного аналізу було визначено, що середня густина 
міофібрилярної тканини була значно нижча в препаратах передсердя, ніж в 
препаратах шлуночка (50±9 і 89±2%, відповідно). Різниця у вмісті міжклітинного 
простору між тканинами передсердя (20±4%) і шлуночка (11±2%) не досягла 
статистичної значимості (P=0.09). Корекція даних щодо пропорції міофібрилярної 
тканини усунула різницю в максимальній силі, підвищила різницю в АТФазній 
активності і незначно збільшила відносну різницю між екстрапольованими 
значеннями АТФазної активності “чистих” ізоформ. Вона також незначно покращила 
кореляцію між АТФазною активністю і вмістом β-ВЛМ. Різниця в середній густині 
міофібрилярної тканини між препаратами передсердя і шлуночка, а також інтра-
трабекулярна мінливість передсердя мають бути взяті до уваги в дослідженнях, де 
використовуються ці препарати. 
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В Главі 3 розглянуто взаємовідносини між функціональними властивостями 
і складом ізоформ ВЛМ у хворому міокарді людини. В порівнянні зі складом ізоформ 
ВЛМ у тканині пацієнтів з регулярним серцевим ритмом, хронічна аритмія 
передсердя супроводжувалася значним зсувом від швидкої α-ВЛМ до повільної β-
ВЛМ (вміст β-ВЛМ був підвищений з 24.6±3.2 до 38.1±5.7% від загального вмісту 
ВЛМ). З іншого боку, як донорська, так і вражена термінально тканина шлуночка, 
містила майже виключно ізоформу β-ВЛМ: лише в двох донорських і одному 
хворому серцевому матеріалі було виявлено ізоформу α-ВЛМ. Економія скорочення і 
інші функціональні властивості були незмінні під час аритмії передсердя і при 
серцевій недостатності на заключній стадії. Однак, чутливість споживання АТФ до 
Са2+ була значно вища при аритмії передсердя, ніж при регулярному ритмі серця, в 
той час як чутливість розвитку сили до Са2+ не відрізнялася у цих препаратах. Це 
означає, що витрати на розвиток сили скорочення передсердя (споживання АТФ 
поділене на ізометричну силу) у пацієнтів з аритмією передсердя зменшуються при 
підвищенні концентрації Са2+. У хворій тканині шлуночка чутливість як сили, так і 
споживання АТФ до Са2+ була підвищена в порівнянні зі здоровою донорською 
тканиною. 
Підвищений вміст β-ВЛМ в здоровій і хворій серцевій тканині корелював зі 
зниженням в споживанні АТФ і в витратах на розвиток сили. На основі цих 
кореляцій можна зробити висновок, що зсув в складі ВЛМ в напрямку збільшення 
вмісту ізоформи β-ВЛМ може бути сприятливим в умовах патології тому, що менше 
енергії потребується для підтримки функції скорочення серця. Оскільки тканина 
шлуночка людини містить переважно β-ВЛМ, цей зсув є менш важливим в 
шлуночках, однак є видатною властивістю хворого передсердя. 
За допомогою гістохімічного аналізу було визначено, що вміст 
міжклітинного простору (переважно зайнятий з’єднувальною тканиною) у здоровій 
тканині передсердь і шлуночка був менший, ніж у хворій тканині. Таким чином 
розвиток фіброзу може також сприяти зниженню скоротливої функції хворого 
міокарду людини (Глава 1, Рисунок 1.1). 
В Главі 4 описано функціональні наслідки деградації сТнІ для серцевої 
тканини людини. Ендогенний сТнІ було замінено на перший продукт деградації сТнІ 
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(сТнІ1-192) або на цілий сТнІ в серцевих міофібрилах і кардіоміоцитах. В присутності 
усіченого сТнІ максимальна сила була незмінна, в той час як швидкості активації та 
повторного розвитку сили, а також кінетика розслаблення були сповільнені. В 
порівнянні із кардіоміоцитами з цілим сТнІ, у препаратах, що містили комплекс 
сТнІ1-192, чутливість скоротливого апарату до Са
2+ була підвищена. Дані результати 
свідчать про те, що деградація сТнІ в людському міокарді в основному погіршує 
функцію діастоли. 
В Главі 5 розглянуто вплив деградації сТнІ на здатність міофіламентів 
реагувати на β-адренергічну стимуляцію і підвищене попереднє навантаження (ефект 
Франка-Старлінга) в людських кардіоміоцитах. Протеїн кіназа А (ПКА)- 
опосередкована десенсибілізація і залежне від довжини саркоміру підвищення 
здатності міофіламентів генерувати силу були збереженні в сТнІ1-192 кардіоміоцитах. 
Це вказує на те, що деградація сТнІ не впливає на β-адренергічні і залежні від 
попереднього навантаження реакції в міокарді людини. 
 
Висновки 
1. Скорочення міокарду людини в 5 разів економніше в тканині шлуночка, ніж в 
тканині передсердя. 
П’ятиразова різниця в економії скорочення є результатом зменшеного споживання 
АТФ тканиною шлуночка, оскільки ніякої суттєвої різниці не було знайдено між 
препаратами шлуночка і передсердя у величині відношення ізометричної сили до 
площі поперечного розрізу. Ця функціональна відмінність має бути взята до уваги 
при використанні результатів, отриманих в тканині шлуночка, для того, щоб робити 
висновки про властивості тканини передсердя, і навпаки. 
 
2. Ізоформа β-ВЛМ людини в 5 разів економніша, однак значно повільніша ніж 
ізоформа α-ВЛМ. 
З кореляцій між швидкістю споживання АТФ і вмістом ВЛМ може бути розрахована 
швидкість споживання волокон з “чистою” ізоформою α-ВЛМ і “чистою” ізоформою 
β-ВЛМ. Зменшення значення витрат на розвиток сили волокон з 100% -ним вмістом 
ізоформи β-ВЛМ є результатом зменшення швидкості споживання АТФ, оскільки не 
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було знайдено жодної кореляції між відношенням ізометричної сили до площі 
поперечного розрізу і вмістом ізоформи β-ВЛМ. 
 
3. В умовах патології зсув у вмісті ВЛМ в напрямку ізоформи β-ВЛМ може бути 
сприятливим в тканині передсердя людини, однак в тканині шлуночка відіграє 
незначну роль або жодної ролі.  
Оскільки ізоформа β-ВЛМ економніша ніж α-ВЛМ, підвищений вміст β-ВЛМ в 
серцевих м’язових волокнах буде сприятливим для хворого серця людини, оскільки 
менше енергії буде потребуватися для підтримки його скоротливої функції. Однак, 
треба зазначити, що при значному серцево-судинному стресі зсув ізоформ ВЛМ 
може стати й несприятливим. Серцевий резерв, необхідний в цих умовах, значною 
мірою визначається швидкістю скорочення міокарду, а вона буде значно сповільнена 
зі зростанням вмісту β-ВЛМ. Дані ефекти характерні переважно для тканини 
передсердя, оскільки здорова тканина передсердя містить лише 25% β-ВЛМ. Тому 
зсув ізоформ ВЛМ, що спостерігався під час захворювання серця (наприклад, аритмії 
передсердя), буде мати значні функціональні наслідки. Тканина шлуночка людини 
переважно містить β-ВЛМ (аж до 100%). Відповідно, зсув ізоформ ВЛМ, що може 
відбутися у деяких людей, буде значно меншим ніж в передсерді і тому матиме 
менший вплив на скоротливу функцію міокарду. 
 
4. Безпосередній вплив змін складу тропоніну на функціональні властивості серцевої 
тканини людини може бути визначений заміною модифікованого тропонінового 
комплексу в препарати серця людини. 
Як було показано за допомогою цифрової мікроскопії, протокол, використаний для 
заміни тропонінового комплексу в людські кардіоміоцити, забезпечує його однорідну 
заміну в кардіоміоцитах. За даних умов замінені кардіоміоцити розвивають 
ізометричну силу, порівняну з не заміненими кардіоміоцитами, і залишаються 
стабільними під час нанесення усього ряду субмаксимальних кальцієвих активації. 
Це робить заміну чудовим засобом для вивчення специфічних наслідків як 
трансляційних, так і пост-трансляційних модифікацій субодиниць серцевого 
тропоніну в серцевій тканині людини. 
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5. Деградація сТнІ з його С-кінця може сприяти діастоличній дисфункції в міокарді 
людини. 
Після заміни тропонінового комплексу в людських серцевих міофібрилах і 
кардіоміоцитах на тропоніновий комплекс з сТнІ1-192, максимальна сила була 
незмінна, що вказує на те, що деградація сТнІ не впливає на функцію систоли. 
Сповільнення кінетик розслаблення і активації і підвищена чутливість до Са2+ 
скоротливого апарату в препаратах, що містили сТнІ1-192, свідчить про те, що 
деградація сТнІ може скоріше погіршувати функцію діастоли і таким чином сприяти 
розвитку серцевої недостатності у людей. 
 
6. Деградація серцевого ТнІ не впливає на β-адренергічні і залежні від попереднього 
навантаження реакції в міокарді людини. 
ПКА- опосередкована десенсибілізація і залежне від довжини саркоміру підвищення 
здатності міофіламентів генерувати силу були збереженні в сТнІ1-192 кардіоміоцитах. 
Це вказує на те, що реакції на серцево-судинний стрес (наприклад, під час фізичних 
вправ) не будуть притуплені в людських серцях, що містять деградований сТнІ. 
 
Підсумовуючи, в цій дисертації було встановлено до якої міри ВЛМ визначають 
енергетичні властивості серцевої тканини людини і показано, що сТнІ відіграє 
головну роль у визначенні її чутливості до Са2+. 
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більше всіх постраждала від моїх нічних звінків. Дякую тобі за твоє терпіння, 
підтримку і любов, тільки з тобою і Леною у мене вийшло закінчити це все. 
 
Dennis, heel erg bedankt voor jou ondersteuning! Het hebben van een vriendin die haar 
proefschrift afmaakt is moeilijk genoeg, maar het hebben van een buitenlandse vriendin is 
bijna onmogelijk! Bedankt voor al je vertalingen, geduld, zorg en liefde! Onse groene 
eiland zal een goede vergoeding voor ons allebei worden ….. 
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